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Zusammenfassung  IV 
ZUSAMMENFASSUNG 
 
Streptococcus agalactiae (Streptokokkus der Serogruppe B (GBS)) ist ein 
grampositives Bakterium und in gesunden Erwachsenen als harmloser Kommensale 
in der gastrointestinalen und vaginalen Flora zu finden. In Neonaten jedoch ist dieser 
Keim einer der Hauptverursacher von Pneumonie, Atemversagen, Bakteriämie, 
Sepsis und Meningitis. Im Rahmen dieser Dissertation konnte ein neues Tiermodell 
für GBS-induzierte Sepsis in einer Maus mit einem humanen Immunsystem 
(humanisierte Maus), generiert werden. Dadurch, dass das Immunsystem von 
humanisierten Mäusen Defizite vergleichbar der von humanen Neugeborenen 
aufweist, ist die humanisierte Maus ein geeignetes Infektionsmodell für humane 
Neugeborene. Dieses neue Tiermodell wurde verwendet um die Effekte zweier 
Medikamente, die routinemäßig in der Klinik eingesetzt werden, auf GBS-Sepsis zu 
untersuchen: Betamethason (Lungenreifung) und Indomethazin (Wehenhemmer). 
Obwohl beide Medikamente vielfach Anwendung in der Perinatalmedizin finden, ist 
wenig über ihre Wirkung auf das neonatale Immunsystem und den Krankheitsverlauf 
bekannt. Anfänglich (24h nach der Infektion) führte Betamethason zu keinen 
ausgeprägten Veränderungen der untersuchten Zytokinspiegel oder 
Leukozytenpopulationen, jedoch induzierte das Medikament eine Verringerung der 
systemischen Bakterienlast in infizierten Tieren. Nach 3 Tagen führten sowohl 
Betamethason als auch Indomethazin zu einer Abnahme von T und B Zellen in der 
Milz, einer Zunahme von B Zellen im Knochenmark (BM) und einem Rückgang 
myeloider Zellen im BM. Diese Veränderungen gingen mit einem Anstieg der 
systemischen Bakterienlast einher. Der Anstieg der systemischen Bakterienlast und 
die Veränderungen der Leukozytenpopulationen im BM nach Indomethazingabe 
waren nicht ausgeprägt, jedoch führte dieses Medikament zu einem Anstieg von 
Interleukin-8 im Serum infizierter Tiere. Beide Medikamente führten zu keinen 
deutlichen Veränderungen in den untersuchten Leukozytenpopulationen oder der 
Bakterienbeseitigung nach länger anhaltender Infektion (7 Tage). Diese Studie zeigt, 
dass beide Medikamente Einfluss auf humane Immunzellen während einer Infektion 
in vivo ausüben. Aufgrund der Tatsache, dass die Behandlung zu einer Erhöhung 
der Bakterienlast führt, was zum Auftreten oder zur Zunahme von Organschäden 
führen kann, sollten beide Medikamente in Kombination mit Antibiotika verabreicht 
werden, um die Bakterienlast zu senken. 
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ABSTRACT 
 
Streptococcus agalactiae (group B streptococcus (GBS)) is a gram-positive 
bacterium and a harmless commensal in the gastrointestinal and vaginal flora of 
healthy adults. In neonates however, GBS is a leading cause for pneumonia, 
respiratory failure, bacteremia, sepsis and meningitis. In this study, a new animal 
model for GBS-induced sepsis is introduced, a mouse featuring a human immune 
system (humanized mouse). The immune system of humanized mice and human 
neonates exhibit similar deficiencies, making the animals a well suited infection 
model for human newborn infants. This novel animal model was used to analyze the 
effect of two drugs routinely used in the clinic: Betamethasone, for fetal lung 
maturation and Indomethacin to prevent labor. Although both drugs are frequently 
utilized in the perinatal care, little is known about their effect on the neonatal immune 
system and on disease progression in GBS-induced sepsis. Initially (1 day post 
infection) Betamethasone treatment did not induce marked changes in cytokine 
levels and leukocyte populations, but resulted in a systemic reduction of live bacteria 
in infected animals. After 3 days, both Betamethasone and Indomethacin led to a 
reduction of T and B cells in the spleen, an increase in B cells in the bone marrow 
(BM) and a decrease in myeloid cells in the BM. These changes in leukocyte 
populations were accompanied by a systemic increase of live bacteria. While the 
systemic increase in live GBS and the changes in leukocyte populations in the BM 
after Indomethacin treatment were not pronounced, the drug led to increased 
interleukin-8 levels in the serum of infected animals. Both drugs did not induce 
prominent changes in the analyzed leukocyte populations and in bacterial clearance 
after prolonged infection (7 days). This study shows that both drugs exerted 
influences on human immune cells in vivo during an ongoing bacterial infection. 
Since treatment also increases the bacterial load, which can induce or increase 
organ damage, both drugs should be given in combination with antibiotics to reduce 
the bacterial burden.  
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1  INTRODUCTION 
1.1 STREPTOCOCCUS AGALACTIAE  
 
1.1.1 BACKGROUND AND DISEASE 
 
Streptococcus agalactiae (group B streptococcus (GBS)) is a leading cause of 
invasive neonatal infection (Anthony 1977; Tissi et al. 1990; Shet & Ferreri 2004; 
Maisey et al. 2009). It is a chain-forming, gram-positive coccus that is characterized 
as catalase-negative, oxidase-negative, hippurate hydrolysis-negative but CAMP-
factor positive. In the early 1930s Rebecca Lancefield established a grouping system 
for hemolytic streptococci based on their hemolytic reaction on blood agar. 
Streptococcus pneumoniae displays alpha hemolysis, characterized by greenish 
zones surrounding the colonies. The color stems from methemoglobin, which is 
oxidized hemoglobin. Beta hemolysis lyses the blood cells completely, therefore the 
hemolysis rings, characteristic for colonies of GBS, are clear. Lancefield also 
classified GBS into serotypes (Ia, Ib and II-VIII) based on precipitin reactions in 
animal models using rabbits and mice (Lancefield & Hare 1935; Larsen & Sever 
2008). Although the causality between streptococcal infection and puerperal sepsis 
was discovered by Louis Pasteur in 1879 (Pasteur 1879), GBS was acknowledged to 
be a harmless commensal bacterium, whereas group A streptococcus has been 
considered to be the major pathogen, responsible for puerperal sepsis until 1938. 
Then, GBS had first been recognized as a clinically relevant pathogen by Fry, who 
described 7 cases of GBS-induced puerperal fever. Three of them had been fatal 
(Fry 1938). Hood and his colleagues associated GBS colonization with increased risk 
of perinatal infection in 1961 (Hood et al. 1961). During the 1970s and 1980s, GBS 
emerged as a significant neonatal pathogen in the USA and Western Europe (Shet & 
Ferrieri 2004). Studies by Gladstone et al. showed that in the 1980s approximately 
50% of all cases of early onset sepsis in neonates were caused by GBS (Gladstone 
et al. 1990). Before the introduction of the intrapartum antibiotic prophylaxis by the 
Center of Disease Control (CDC) in the late 1990s and the revised guidelines by the 
CDC in 2002, 2 of 1000 births displayed early onset disease (EOD) with invasive 
GBS infection and sepsis. The prophylactic treatment implemented by the CDC 
includes universal screening of pregnant women for GBS colonization between 35 
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and 37 weeks of gestation. Subsequently all women carrying GBS are treated with 
intravenous antibiotics. This led to a decline of EOD from 2 per 1000 to 0.5 per 1000 
births (Revised CDC Guidelines 2002; Larson & Sever 2008; Rajagopal 2010). 
Although the intrapartum antibiotic prophylaxis significantly reduces the incidences of 
EOD, it does not have a beneficial effect on the number of late onset diseases 
(LOD), GBS related stillbirth or prematurity. Another major problem is the emergence 
of antibiotic-resistant strains. Since GBS is sensitive to penicillin, chemoprophylaxis 
is usually intravenous treatment with Penicillin G. If the women have an allergy to 
penicillin, they are treated with Clindamycin or Erythromycin. However, 15-30% of 
GBS strains are resistant to Clindamycin and Erythromycin. Furthermore Penicillin-
resistant strains have also emerged recently (Shet & Ferrieri 2004; Larson & Sever 
2008; Rajagopal 2010). 
Despite intrapartum chemoprophylaxis, GBS still is the most frequent bacteria in term 
infants (Stoll et al. 2011) and invasive GBS infection of neonates still remains a 
leading cause of sepsis, bacteremia, pneumonia and meningitis (Schuchat et al. 
2001; Moore et al. 2003; Henneke & Berner 2006, Maisey et al. 2009; Tazi et al. 
2012).  
There is a classification of GBS infections depending on the time point of disease 
manifestation. When the infection presents in infants between the first few hours of 
life and 7 days, it is defined as EOD. Usually EOD manifests within the first 24 h after 
birth. More than 80% of infants suffering from EOD display respiratory distress. Most 
infants present with pneumonia, respiratory failure, bacteremia and sepsis. EOD also 
presents with vascular thrombosis and parenchymal hemorrhage, but despite high 
amounts of GBS in the brain, no leptomeningeal inflammation occurs. Between 5 and 
10% develop meningitis. EOD has a mortality rate of 10-15%. The predominant GBS 
serotypes, responsible for 78-87% of EOD are Ia, III and V (Cowgill et al. 2003; Shet 
& Ferrieri 2004; Maisey et al. 2009). Since maternal colonization with GBS is a 
prerequisite for development of EOD (Rajagopal 2010), the most common route for 
EOD is the transfer of GBS from the mother to the child in utero. Here, bacteria from 
an ascending vaginal GBS infection contaminate the amniotic fluid. This generally 
happens after rupture of the amniotic membranes. When the fetus aspirates amniotic 
fluid, GBS are inhaled and reach the lungs where they damage pulmonary epithelial 
cells. This not only leads to pneumonia and respiratory distress, which are very 
common for EOD, but also to an intravascular uptake of GBS. When the fetus is 
unable to rapidly eliminate the bacteria in the bloodstream, bacteremia followed by 
severe sepsis occurs (Spellerberg 2000). Studies have shown that GBS is able to 
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cross intact chorioamniotic membranes. The subsequent infection and events often 
result in stillbirth or even death of the neonate shortly after birth (Galask et al. 1984). 
Another route for GBS infection is the vertical transmission from mother to child 
during the passage through the birth canal.  
LOD is defined by an onset of disease 7-90 days after birth, with a median onset of 
one month. Serotype III is the predominant GBS serotype in LOD (50%), followed by 
Ia (27%) and V (14%). Although the pathogenesis of LOD is not fully understood yet, 
it is generally acknowledged that horizontal as well as vertical transmission is 
possible. GBS infection can be acquired from contact with infected infants, health 
care workers, close contact with the mother and breast feeding. LOD is usually 
characterized by bacteremia which can quickly progress to meningitis (40-60%) or 
sepsis. There are also reports that GBS infection can lead to osteoarthritis. The 
presentation with respiratory distress or pneumonia is rather uncommon due to a 
different route of infection compared to EOD. Although the mortality rate of LOD is 
quite low (2-6%), 20% of the neonates surviving GBS meningitis suffer from 
permanent neurological sequelae. These include seizures, cortical blindness, mental 
retardation and sensorineural hearing loss. Interestingly enough, the pathophysiology 
of GBS meningitis differs depending on the time of onset. In contrast to EOD, LOD 
usually presents with diffuse purulent arachnoiditis (Berman & Baker 1966; Quirante 
et al. 1974; Shet & Ferrieri 2004; Maisey et al. 2009). 
 
1.1.2 VIRULENCE FACTORS OF GBS THAT FACILITATE UPTAKE OF 
PATHOGEN 
 
In healthy adults, GBS is a commensal of the human intestinal microflora and also 
part of the vaginal microbiota in approximately 25% of healthy women without 
causing any symptoms, let alone a serious infectious disease (Campell et al. 2000, 
Rajagopal 2009; Tazi et al. 2011). However, under certain circumstances, e.g. in 
neonates or immune compromised adults, GBS has the ability to cross barriers (e.g. 
lung and placenta epithelium and blood brain barrier), invade host tissue, elude the 
immune system and cause a severe invasive bacterial infection. To accomplish this 
task, GBS expresses a myriad of soluble and surface-bound virulence factors, 
enabling the pathogen to interact with host cells and avoid clearance by the immune 
system (Maisey et al. 2009; Rajagopal 2009).  
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For bacteria to cause disease, they must overcome various barriers. Most of the 
mechanisms for barrier-crossing involve initial binding to host cells. Studies showed 
that GBS is able to adhere to human epithelial cells through low avidity interactions 
of lipoteichoic acid (LTA), which is part of the GBS cell wall. Also, high affinity 
interactions help strengthen the bond between the host cell and the pathogen. Those 
are mediated by bacterial surface proteins which mostly bind to components of the 
extracellular matrix of the host cells. The strength of these interactions is increased 
under low pH conditions, typical for vaginal mucosa (Maisey et al. 2009). GBS-
binding to laminin is mediated by the laminin binding adhesin (Lmb) (Spellerberg et 
al. 1999). FbsA binds the bacterial surface to fibrinogen (Schubert et al. 2004) and 
Srr1 attaches to keratin 4 (Samen et al. 2007). Among other functions in immune 
evasion, the cell surface protein ScpB attaches to fibronectin as well as to integrins 
(Cheng et al. 2002; Brown et al. 2005). General adherence to host cells is further 
facilitated by the surface proteins LrrG, BibA and the two pilus proteins PilA and PilC 
(Seepersaud et al. 2005; Dramsi et al. 2006; Santi et al. 2007).  
Four strategies are commonly acknowledged for bacteria to overcome barriers like 
the blood brain barrier (BBB). The first one is the transcellular pathway, usually 
including receptor mediated uptake and cytoskeletal modulation. The second option 
is the paracellular pathway, which includes transient or permanent opening of tight 
junctions between the host cells. A third route for bacteria to cross barriers is the 
destruction of the cells that compose the barrier through cytotoxic effects. Another 
way of circumventing barriers is the so called “Trojan Horse Strategy”. Here, the 
bacteria facilitate their own uptake by a leukocyte and cross the barrier inside an 
infiltrating immune cell (Tazi et al. 2012). GBS is thought to use all of these 
pathways, and expresses a variety of virulence factors to accomplish this task. 
In order to overcome barriers using the transcellular pathway, GBS secrets toxins 
and expresses invasins, which are surface-bound virulence factors that promote 
bacterial entry into host cells. Entry into host cells (mostly epithelial cells) is not only 
a possibility to cross barriers, it is also a survival niche for GBS, where the pathogens 
are protected from immune surveillance. GBS secretes hyaluronate lyase, a protease 
that cleaves hyaluronan, thereby degrading a chief component of the extracellular 
matrix. High concentrations of hyaluronan are found in lung and placenta but also in 
other tissues. Hyaluronate lyase is thought to facilitate the spread of GBS during an 
infection since studies determined that GBS found in neonates with bacteremia 
display high concentrations of this enzyme compared to GBS that colonize neonates 
asymptomatically (Rajagopal 2009). An important protein for epithelial cell invasion is 
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the surface associated alpha C protein (ACP). ACP enables host cell invasion 
through interaction with glycosaminoglycan (Baron et al. 2004). ACP also possesses 
a second mechanism for entering host cells, by binding to α1β1- integrins on the host 
cell surface (Bolduc 2007). For the uptake of bacteria by the host cell, the 
cytoskeleton needs to be rearranged. Therefore GBS directly activates Rho 
GTPases (RhoA, Rac1 and CDC42), which regulate intracellular actin 
polymerization. GBS can activate focal adhesion kinase (FAK) and paxillin, but also 
the phosphoinosiotide-3 kinase (PI3K) pathway. Thus GBS actively induces host cell 
cytoskeleton rearrangement, which in turn leads to the internalization of the bacteria 
(Fettucciari et al. 2011).  
Although the exact mechanism or virulence factors for GBS to be able to use the 
paracellular pathway are not discovered yet, Soriani and colleagues found that GBS 
can induce transient opening of junctions (Soriani et al. 2008).  
It is evident from the extensive lung endothelial as well as epithelial damage in 
severe EOD, that destruction of host cells to compromise their barrier function is an 
important mechanism for entry of GBS into the bloodstream (Nizet et al. 1996; 
Gibson et al. 1999). The pore-forming toxin primarily responsible for the lysis of host 
cells is β-haemolysin/cytolysin (β-H/C). Interestingly enough, this toxin promotes lung 
epithelial cell invasion as well as the release of interleukin (IL)-8 even at subcytolytic 
doses, suggesting an additional alternative mechanism for entry besides cell lysis 
(Doran et al. 2002). Furthermore, β-H/C promotes liver failure, impairs cardiac 
function, and contributes to neurological sequelae by inducing inflammatory 
responses (Rajagopal 2009). Dipalmitoylphosphatidylcholine (DPPC), part of the 
lung surfactant, counters not only the cytolytic but also the pro-inflammatory as well 
as the pro-invasive effects of β-H/C (Nizet et al. 1996). This might help explain why 
premature neonates, which lack sufficient surfactant production, have an increased 
risk for EOD.  
Another cytolytic protein released by GBS is CAMP factor. Studies have shown that 
CAMP factor forms pores by oligomerization in host cell membranes, leading to their 
lysis (Lang & Palmer 2003). Since CAMP factor is not affected by the presence of 
DPPC, this virulence factor might play an important role for GBS pathogenesis in 
term neonates with normal surfactant production and presence (Rajagopal 2009).  
GBS further expresses a surface-bound glycolytic enzyme called glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). This enzyme facilitates not only the binding of 
host plasminogen to the GBS surface, it also activates this pro-enzyme to acquire 
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plasmin. Plasmin is a highly tissue-destructive, broad spectrum serine protease, 
capable of breaking down the extracellular matrix (ECM). Not only does surface-
associated plasmin enable GBS to overcome barriers, it is also thought to protect the 
bacteria from the host immune system since the foreign pathogen is covered with 
host protein from the ECM and might therefore be regarded as ‘self’ (Kinnby et al. 
2008; Maisey et al. 2009).  
Studies have shown that upon phagocytosis GBS is able to survive inside of 
macrophages for up to 48 h (Cornacchione et al. 1998). GBS also possesses the 
ability to avoid antimicrobial responses of macrophages and even induce 
cytoskeleton degradation and apoptosis after invading those host cells (Fettucciari et 
al. 2011). This suggests that GBS can cross barriers inside of leukocytes, kill their 
host cells subsequently and colonize tissue protected by cellular barriers like the 
brain. 
 
1.1.3 VIRULENCE FACTORS OF GBS FOR IMMUNE EVASION 
 
GBS not only expresses virulence factors that facilitate its invasion of various tissues 
and the host in general, it also expresses various proteins for immune evasion. 
These factors either reduce or even prevent recognition or help neutralizing host 
defense mechanisms of the innate immune system, which in turn increases the 
survival of GBS.  
The complement system is a crucial component of the innate immune system. It is 
essential for opsonization of pathogens, which drastically increases the detection and 
phagocytosis by macrophages and neutrophils and enables lysis of bacteria through 
formation of a membrane attack complex. Furthermore, it also induces chemotaxis in 
phagocytes (Abbas et al. 2007; Maisey et al. 2009). In order to elude recognition and 
destruction, GBS has developed several strategies to avoid opsonization with 
complement.  
An important factor for GBS virulence is the thick layer of sialic acid-rich capsular 
polysaccharide (CPS). The CPS defines the serotype (Ia, Ib, II-VII and the recently 
discovered IX) of GBS since each strain has a different arrangement of 
monosaccharides (glucose, galactose, N-acetylglucosamine and sialic acid), 
resulting in serotype specific epitopes. The arrangement of monosaccharides differs 
from strain to strain, however they share the terminal sialic acid, N-acetylneuraminic 
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acid (Lewis et al. 2007; Maisey et al. 2009). This terminal sialic acid prevents the 
deposition of C3, thereby blocking the alternative pathway of the complement system 
(Edwards et al. 1982). The thick polysaccharide capsule also prolongs the survival of 
GBS upon phagocytosis (Charland et al. 1996).  
Not only does GBS prevent C3 deposition, the pathogen also expresses additional 
proteins that synergistically work together to inhibit complement activity. The surface-
bound protein BibA not only facilitates adhesion of GBS to host cells, it further binds 
to human C4b binding protein (C4BP), which is a regulator of the classic and the 
lecithin pathway of the complement system. C4BP increases decay of C3-
convertases and helps degrade C3b and C4b, thereby inhibiting complement activity 
(Santi et al. 2007; Zadura et al. 2009). With the help of the GBS β-protein, the 
bacteria also bind another regulator of complement activity, complement factor H 
(CFH) (Hellwage et al. 2004). CFH accelerates the degradation and inhibits new 
formation of C3-convertases. Furthermore it facilitates cleavage of C3b (Alexander & 
Quigg 2007). As described above, GBS recruits host proteins to thwart complement 
activity. However it also expresses own enzymes that affect the complement system, 
like the C5a peptidase ScpB. This enzyme cleaves human C5a, which is not only an 
anaphylatoxin but also an important chemoattractant for neutrophils. Thus ScpB 
reduces recruitment of neutrophils (Takahashi et al. 1995).   
Also important for fighting off bacterial infections are cationic antimicrobial peptides 
(AMP) like defensins and cathelicidins, which also belong to the innate immune 
system (Hancock & Diamond 2000). AMPs are positively charged and therefore have 
an electrostatic affinity for the negatively charged LTAs in the cell wall of gram 
positive bacteria. Once bound to the surface of pathogens, AMPs form membrane 
pores that disrupt membrane integrity which kills the pathogens. By incorporation of 
positively charged D-alanine residues into the LTAs, GBS reduces the negative 
surface charge and therefore its affinity for AMPs (Poiart et al. 2001; Gallo & Nizet 
2003). The surface bound penicillin-binding protein PBP1a and the pilus backbone 
protein PilB also increase the resistance of GBS to AMPs (Hamilton et al. 2006; 
Maisey et al. 2008).  
GBS expresses a number of virulence factors preventing opsonization by 
complement and subsequent phagocytosis by neutrophils and macrophages. 
However, if the pathogen is taken up by a phagocyte, it is still able to avoid being 
killed and degraded by the leukocyte.  
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The antioxidative carotenoid pigment produced by GBS neutralizes hydrogen 
peroxide (H2O2), hypochlorite (ClO
-), superoxide anions (O2
-), and singlet oxygen 
(1O2). A study by Liu and colleagues implies that this carotenoid enables the bacteria 
to survive oxidative bursts from phagocytes of premature or septic neonates, which 
display a diminished oxidative burst function (Liu et al. 2004).   
Another protein, providing resistance to reactive oxygen species (ROS), is the 
superoxide dismutase SodA. This enzyme transforms 2 O2
- + 2 H+ into O2 + H2O2, 
which is subsequently metabolized by other enzymes (Poyart et al. 2001).  
Due to 100-fold higher oxygen metabolite scavenger glutathione and 10-fold higher 
glutathione reductase concentrations, the catalase negative GBS resists 10x higher 
H2O2 concentrations than catalase-positive Staphylococcus aureus (Wilson & 
Weaver 1985). Catalase converts 2 H2O2 to O2 and 2 H2O. 
 
1.2 NEONATAL IMMUNE SYSTEM 
 
In the western world, the mortality in the first 60 years of life is highest in the very first 
year. There, most deaths occur at the very beginning in the first 3 days of life. 
Interestingly enough, this is the same time when severe bacterial infections and 
sepsis are most frequent (1-10 per 1000 neonates) (Berner 2005). As mentioned 
above, before implementing intrapartum antibiotic prophylaxis, almost 50% of early 
onset sepsis within 72 h after birth were caused by GBS (Gladstone et al. 1990). 
Severe invasive GBS infections almost exclusively occur in neonates, elderly, or 
immunocompromised individuals (Maisey et al. 2009), whereas colonized healthy 
adults typically show no symptoms of infection or disease (Rajagopal 2010).  
This raises the obvious question if the immaturity of the neonatal immune system 
plays a prominent role in the susceptibility of neonates to GBS induced sepsis, 
especially since the risk of developing an invasive GBS infection increases with 
immaturity of the child. GBS-associated disease develops in 0.5-1% of term 
neonates in contrast to 15-20% of preterm neonates from colonized mothers. If the 
prematurity is very pronounced, below 28 weeks of gestation, the risk of developing 
an invasive GBS infection increases up to 100% (Schuchat 2001; Berner 2005).  
The importance of the immaturity and the deficiencies of the neonatal immune 
system for the susceptibility to GBS infection was demonstrated in animal studies of 
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mice. Mancuso and colleagues showed that in neonatal mice, subcutaneous injection 
of 30 GBS resulted in the death of 60% of the animals. In adult mice the lethal dose 
for 60% of the infected animals was 5x107 GBS, which represents a more than 106-
fold higher dose (Mancuso et al. 2004). 
The immune system is composed of two branches, the innate immunity and the 
adaptive immunity. The innate immunity contains the following components: physical 
(epithelial) as well as chemical (antimicrobial factors e.g. lysozyme) barriers, blood 
proteins (complement factors, defensins …), cellular components like phagocytes 
(neutrophils, macrophages) and natural killer cells, as well as regulatory proteins 
called cytokines which regulate the innate immune response and help activate the 
adaptive immune response. The innate immunity reacts very rapidly to pathogens 
(within hours) and contains the infection by killing invading pathogens and preventing 
systemic dissemination. It further activates the adaptive immune system, consisting 
of cellular (B and T cells) and humoral (antibodies, cytokines) components. The 
response of the adaptive branch of the immune system is slower (within days) but 
also more specific (high diversity of B and T cell receptors) and also possesses an 
immunological memory, resulting in a faster, more specific and stronger immune 
response after repeated exposure to the same pathogen (Abbas et al. 2005).   
Although the neonatal immune system is able to mount successful immune 
responses in term as well as preterm infants, it exhibits several limitations and 
deficiencies in both the innate as well as in the adaptive branch compared to the 
mature adult immune system.  
 
1.2.1 T CELLS 
 
The fetal immune system develops without contact to pathogens or foreign antigens 
since the amniotic cavity resembles a sterile environment. Under normal 
circumstances, the first contact with microbes occurs inside the birth canal during 
birth (Berner 2005). Therefore, 97% of neonatal T cells feature a naïve phenotype 
(CD45RA+). In addition to the naivety, which is the presumed reason for a markedly 
diminished expression of IL-4 and interferon-γ (IFNγ) upon activation, neonatal T 
cells display several defects (Schelonka & Infante 1998; Chalmers et al. 1998). 
Activated neonatal T cells produce lower amounts of IL-2 and IL-6 (Watson et al. 
1991; Chalmers et al. 1998) and don’t fully obtain the adult phenotype since they 
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express less CD25 (activation marker) but keep expressing CD38 (immaturity 
marker) (Hassan & Reen 1997). The lower production of IL-2 could be the reason for 
their diminished activation-induced proliferation upon stimulation in vitro, compared 
to adult T cells (Gasparoni et al. 2003). Considering the reduced cytokine production, 
it is not surprising that D’Arena and colleagues discovered the markedly decreased 
ability of neonatal T cells for executing Th1 or Th2 responses (D’Arena et al. 1999). 
The reduction in IFN-γ production is more pronounced than the reduction in IL-4 
production. This could explain why the immune response of neonates is skewed 
towards Th-2 (Vigano et al. 1999; Adkins et al. 2003; Adkins et al. 2004). 
Furthermore, neonatal T cells express lower amounts of CD40 ligand (CD40L), which 
is an essential ligand for B cell activation and immunoglobulin (Ig) class switching 
(Schelonka & Infante 1998; Polin et al. 2004).  
 
1.2.2 B CELLS 
 
In neonates the humoral immune response is delayed in onset, has a shorter 
duration and releases lower amounts of Ig, which have lower average affinity and 
heterogeneity. It also contains lower amounts of IgG2, which is the prominent IgG 
subclass induced in response to bacterial capsular polysaccharides (Sanders et al. 
1995; Adkins et al. 2004).  
Similar to the neonatal T cell population, the naïve phenotype (CD5+) composes the 
majority of the neonatal B cells. They produce primarily IgM and only low amounts of 
IgG and IgA upon stimulation, which accounts for the reduced affinity of neonatal 
antibodies. The overall amount of Ig produced by neonatal B cells is also markedly 
lower compared to adult B cells (Schelonka & Infante 1998; Splawski et al. 1991). 
Furthermore, these immature B cells show a distinctly lower upregulation of major 
histocompatibility complex (MHC) class II and co-stimulatory factors (e.g. CD86) 
upon activation (Marshall-Clarke et al. 2000). The expression of CD21 (complement 
receptor 2) is also diminished. This likely results in weaker activation after binding of 
antigen/C3d to CD21/CD19/CD81 B cell co-receptor complex. The decreased 
amount of C3 in neonatal blood exacerbates this deficiency. The reduced 
expressions of the chemokine receptor 7 (CCR7) and the cell adhesion molecule 
CD62L (L-selectin) are probably the cause of homing defects in neonatal B cells 
(Tasker & Marshall-Clarke 2003). Furthermore B cells from neonates not only 
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express lower amounts of the cytokine receptors for IL-4 and IL-5 and the IL-2 
receptor γ chain (IL-2RG) compared to their adult counterparts, they also display a 
decreased upregulation of IL-2RG upon stimulation with IL-2 and IL-4 (Zola et al. 
1995; Saito et al. 1996). Since IL-4, IL-5 and the IL-2RG play a prominent role in 
growth, maturation, class switching, and antibody secretion (Beagley et al. 1988; 
Mandler et al. 1993; Recher et al. 2011), the phenotype of the neonatal B cell surface 
molecules correlates very well with the reduced antibody response in neonates 
compared to adults. But not only the surface phenotype is different, also intracellular 
signaling varies. Crosslinking of surface Ig with CD21 leads to intracellular increase 
of Ca2+ and enhanced antibody production in adult B cells. In neonatal B cells the 
same treatment has no effect on intracellular Ca2+ levels or Ig production (Landers et 
al. 2005). 
Neonates produce markedly lower amounts of IgG2 compared to adults. This 
antibody subclass is produced in response to T cell-independent type 2 (TI-2) 
antigens (bacterial polysaccharides with high molecular weight) (Adkins et al. 2004; 
Saunders et al. 2005). A major B cell subset that responds to TI-2 antigens and 
subsequently produces IgG2 is the marginal-zone B cell (Martin et al. 2001). 
Neonates only exhibit few marginal-zone B cells. These cells start to develop at the 
age of 1-2 years and their emergence coincides with the production of specific 
antibodies against polysaccharides (Timens et al. 1989; Rijkers et al. 1998; Adkins et 
al. 2004).  
The deteriorated antibody response of neonates is not only based on deficient 
neonatal B cells. Structural defects as well as shortcomings in other neonatal 
leukocytes (T cells, macrophages, dendritic cells …) contribute to the reduced 
antibody response (Landers et al. 2005).  
For the activation of B cells and subsequent antibody production by T cell-dependent 
(TD) antigens, lymphoid follicles, follicular-dendritic-cell networks and germinal 
centers are essential. Animal studies on neonatal mice have shown that these 
structures do not exist at birth. This probably also contributes to the diminished 
antibody response of neonates (Adkins et al. 2004).  
Infant susceptibility to GBS is most pronounced in the first 3 months of life. This 
coincides well with lower levels of IgM, diminished antibody responses (especially 
against capsular polysaccharide antigens) and low levels of the specific antibodies 
IgG and IgA. The lack of antibody responses against capsular polysaccharides is 
even exacerbated in GBS infection, since the GBS capsular polysaccharide mimics 
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the human Lewis antigen and therefore has low immunogenicity (Kasper et al. 1979). 
Also, the VH gene repertoire utilized for the variable chain of the B cell receptor is 
more constrained and the terminal deoxynucleotidyl transferase, which provides 
junctional diversity in the hypervariable CDR3 region adds fewer nucleotides (adults: 
8 between VH and DH and 6 between DH and JH – neonates: 3 and 2). (Zemlin et al. 
2001; Bauer et al. 2002; Berner 2005).  
Although there is a transplacental IgG transfer from the mother, this mechanism only 
partially compensates for the lack of neonatal IgG production. And since the IgG 
transfer occurs mainly in the last trimester, preterm neonates not only possess an 
even more immature immune system, but also lack the protection by maternal IgG 
(Chirico 2005). Furthermore, infants from mothers without GBS-specific IgG are at a 
disadvantage when being infected with GBS.  
 
1.2.3 MONOCYTES/MACROPHAGES 
 
Although studies of neonatal (cord blood) human monocytes exist, the results are 
incoherent and often contradicting. Studies that analyzed the cytokine production (IL-
1, IL-6, IFN-γ, tumor necrosis factor (TNF)) of cord blood monocytes for example 
vary in their results, describing lower, equal or even elevated expression compared 
to adult monocytes upon stimulation. These conflicting results most likely stem from 
the cell population used for the experiment (whole blood, mononuclear cells (MNC), 
monocytes/macrophages) and also which agent was used for stimulation (LPS, 
phytohemagglutinin, bacteria) (Landers et al. 2005). Studies describe equal 
deficiencies in neonatal T cells, B cells, and neutrophils for humans and mice. Due to 
the inhomogeneous results from human studies, the findings of mouse experiments 
will be described in the following paragraph. 
Phenotypically, neonatal murine splenic macrophages are mature, since they 
express similar or even higher amounts of the macrophage marker molecules Mac-1, 
F4/80, MHC class II, and SR-A (Chelvarajan et al. 2004). Chelvarajan and 
colleagues showed that neonatal macrophages express lower amounts of Toll-like 
receptor (TLR)-2, TLR-4 and CD14, responsible for activation of macrophages by the 
ligands peptidoglycan or LPS, respectively (Aderem & Ulevitch 2000; Chelvarajan et 
al. 2004). They also showed that upon activation with LPS (also bacteria and 
peptidoglycan), neonatal macrophages expressed markedly lower amounts of TNF, 
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IL-1β, IL-6 and IL-12 compared to stimulated adult cells. However, the neonatal 
macrophages produced significantly more IL-10 (Chelvarajan et al. 2004). As 
experiments with cells from IL-10 knockout mice have shown, the increased IL-10 
expression by stimulated neonatal macrophages is mostly responsible for the low 
production of the pro-inflammatory cytokines IL-1β and IL-6. This probably is a 
contributing factor for the Th2 bias of the neonatal immune system, and the 
susceptibility to bacterial infections. This cytokine profile also seems to be, at least 
partially, responsible for the unresponsiveness of neonatal B cells to TI antigens, 
since substitution of IL-1β and IL-6 or anti-IL-10 antibodies enhances neonatal 
response to TI antigens (high molecular weight polysaccharide) (Chelvarajan et al. 
1998; Chelvarajan et al. 2004; Landers et al. 2005).  
In summary, the cytokine profile of neonatal macrophages upon activation with 
bacterial antigens is most likely partially responsible for the Th2 shift of the neonatal 
immune response, and the inability of the B cells to produce antibodies against 
antigens like bacterial polysaccharide.   
 
1.2.4 DENDRITIC CELLS 
 
Dendritic cells (DC) are professional antigen presenting cells (APC), essential for 
initiating an adaptive immune response. After taking up a foreign antigen in 
peripheral tissue, DC process and display it on MHC complexes on their surface. 
They upregulate the expression of activation markers and MHC complexes and 
migrate to the draining lymph node where they present the antigen together with co-
stimulatory molecules to T cells. This process initiates an adaptive immune response 
(Steinman 1991; Banchereau & Steinman 1998). 
Human neonatal DC (differentiated from cord blood monocytes) display a phenotype 
that is similar to their adult counterparts (surface CD11c expression, etc.). However, 
Goriely et al. showed that after their activation, expression of the important 
maturation markers HLA-DR, CD40, CD80 and CD86 are lower compared to adult 
DC. Neonatal DC also display diminished phagocytic capacity, which is essential for 
the uptake of antigens (Liu et al. 2001). Upon stimulation (LPS, CD40 ligation, poly 
I:C) they also produce very low amounts of IL-12. Due to this defect, neonatal DC are 
less potent to induce IFN-γ production in CD4+ T cells (Goriely et al. 2001; Langrish 
et al. 2002; Landers et al. 2005). Because of that, neonatal DC are less effective in 
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inducing and sustaining T cell proliferation following antigenic stimulation (Langrish et 
al. 2002). In contrast to neonatal monocytes/macrophages, DC not only express 
similar amounts of TLR-4, but also similar amounts of TNF and IL-10 compared to 
adult DC upon LPS stimulation. Therefore, the reduced IL-12 expression, resulting in 
lower IFN-γ production, is probably determined intrinsically. That the reduced IL-12 
production of neonatal DC contributes to the skewing of the immune response 
towards Th2 was shown by Arulanandam and colleagues. They could induce a Th1 
response by using IL-12 as an adjuvant (Arulanandam et al. 1999).  
Deficient DC and monocytes/macrophages are the reason for the diminished 
neonatal IFN-γ production (Chirico 2005). Not only are both cell types producing less 
pro-inflammatory cytokines (IL-12, TNF, IL-1, IL-6), they are producing equal (DC) or 
even higher amounts (macrophages) of anti-inflammatory IL-10 compared to adult 
cells. This most likely is a major contributing factor for the Th2 bias of the neonatal 
immune response. 
 
1.2.5 NEUTROPHILS 
 
Neutrophils are often described as the first line of defense of the innate immune 
system since they are the first leukocytes to be recruited to the site of infection. 
These cells contain bacterial and fungal infections by phagocytosis and digestion, 
secretion of antimicrobial substances (degranulation), and catching and killing 
pathogens with so called neutrophil extracellular traps (NET) (Segal 2005; Hickey & 
Kubes 2009). 
In order to migrate to the site of infection neutrophils follow an increasing gradient of 
chemotactic factors. Neonatal neutrophils display only 33 – 50% of the chemotactic 
ability of their adult counterpart (Wolach et al. 1998). In neutrophils from term and 
more so from preterm infants, several deficiencies in chemotaxis were found 
(Anderson et al. 1981; Carr et al. 1992; Klein et al. 1977; Pahwa et al. 1977; Wolach 
et al. 1998; Carr et al. 2000). First of all, in very preterm infants, the total neutrophil 
cell mass is decreased (Carr et al. 2000). Second, rolling adhesion (migration) to 
activated endothelium and transmigration to the subendothelial tissue are decreased 
in cells from newborn infants compared to adult cells (Anderson et al. 1991). Third, 
the formation of lamellipodia and directed movements towards a stimulus are 
impaired in neonatal cells (Anderson et al. 1981). Chemotaxis in term, especially in 
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preterm infants, is further impaired by lower expression of L-selectin which controls 
neutrophil rolling along the endothelium (Anderson et al. 1991; Mariscalco et al. 
1998). In addition to that, neonatal neutrophils display a reduced ability to polymerize 
monomeric G-actin, which would (at least partially) explain the impaired migratory 
abilities (Sacchi et al. 1987; Harris et al. 1993; Merry et al. 1998). Interestingly 
enough, neutrophil chemotaxis improves very quickly after birth, and reaches adult 
values in about 10 days. This development takes considerably longer in very preterm 
infants (Carr 2000). 
Wolach et al. showed that although the superoxide anion (O2
-) production in neonatal 
neutrophils is not impaired, their bactericidal activity (killing of E. coli) is just 33% of 
the adult cells (Wolach et al. 1998). Furthermore, neonatal neutrophils are incapable 
of NET formation (Yost et al. 2009) 
Upon infection, most neutrophils are rapidly recruited from the storage pool in the 
bone marrow to fight off infections. Also the generation of new neutrophils in the 
proliferative pool, consisting of proliferating pluripotent myeloid and unipotent 
neutrophil progenitor cells is increased (Cairo 1989; Berner 2005). Christensen et al. 
performed in vivo experiments, where neonatal and adult rats were infected with 
GBS followed by an analysis of the neutrophil proliferative pool, the neutrophil 
storage pool, the circulating blood neutrophil concentration and the immature to total 
neutrophil ratio in the blood. They showed that adult rats develop neutrophilia 
(>300% of circulating mature neutrophils compared to non-infected controls) 24 h 
post infection. The adult neutrophil storage pool decreased in the beginning (to 65%) 
but increased above 100% after 48 h of infection. And although the neutrophil 
proliferative pool itself didn’t increase, the number of neutrophil progenitors and 
proliferating cells in the bone marrow increased (300%). The neutrophil response in 
the neonatal rats depicted a distinctly different picture. In contrast to the adult 
animals, neonatal rats developed severe neutropenia (aggravated by the fact that 
90% of circulating cells were immature) after 15 h of infection. Also the neutrophil 
storage pool depleted rapidly (30% after 2h; 9% after 15 h compared to controls). 
The dramatic decrease of the neutrophils in both blood and bone marrow was 
exacerbated by the reduction of neutrophil progenitors and proliferating cells in the 
bone marrow (48%) after 15 h (Christensen et al. 1982). An explanation for 
neutropenia and rapid depletion of the bone marrow storage pool in human term and 
pre-term infants could be the proliferation rate of neonatal neutrophil progenitors. 
These cells proliferate at a much higher level compared to adult cells (cells in 
proliferative state: 55% to 7%). This high (possible maximum) level of proliferation 
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could mean that there is no possibility to increase the proliferation in case of infection 
(Christensen et al. 1986).  
It is generally acknowledged that, although reduced chemotaxis and bactericidal 
activity play a role, the crucial factor for the deficient neutrophil activity in neonates is 
the small (25% of adult cell number, suggested by animals studies) and rapidly 
exhausted neutrophil storage pool (Chircio et al. 2005; Melvan et al. 2010) and 
possibly also the inability to increase progenitor proliferation.  
 
1.3 HUMANIZED MOUSE MODEL 
 
Immune responses, drug and vaccine efficacies as well as disease progression are 
complex processes and can only be studied in vivo, not in vitro. Studying the human 
immune response in vivo is very limited and severely restricted by ethical and legal 
restrictions as well as technical constraints (Shultz et al. 2007). Therefore, various 
scientists claim that there is the growing need for appropriate animal models to study 
human hematopoiesis, immunity, graft rejection, human specific viruses, infections, 
vaccines and treatments etc. in vivo (Shultz et al. 2005; Shultz et al. 2007). A number 
of pathogens are either specific for humans or causing human-specific immune 
responses, which diverge from the responses in other animals. Examples for these 
infectious agents are human immunodeficiency virus (HIV), Epstein Barr virus (EBV), 
Dengue virus, hepatitis B virus (HBV), hepatitis C virus (HCV), Plasmodium 
falciparum and Mycobacterium tuberculosis. To study HIV infection, primates like 
chimpanzees, which are closely related to humans have been used. However, 
chimpanzees are not only expensive and experiments using these animals are 
burdened with ethical concerns, infected animals also don’t mirror the human 
disease progression, since chimpanzees don’t develop acquired immune deficiency 
syndrome (AIDS) (Shultz et al. 2007; Watanabe et al. 2007; Legrand et al. 2009; 
Shultz et al. 2011).  
The most common animal for research is the mouse (mus musculus), which has 
been and still is enabling many important research advances. The advantages of 
mice as a model system are: high homology with humans, completely sequenced 
genome, easy genetic manipulation (transgenic animals), quick reproduction, and 
being small animals, they are relatively inexpensive to breed and easily maintained 
(Adinstruments 2012). However, despite the high homology between humans and 
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mice, and all the above-mentioned benefits, the mouse is often not a very suitable 
model for the human immune system. Mestas and Hughes describe more than 60 
differences between the human and the murine immune system (Mestas & Hughes 
2004). They include differential expression of TLR 2/3/9/10, different Ig isotypes and 
CD1 genes, size of leukocyte populations (human: 30-50% lymphocytes and 50-70% 
neutrophils vs mouse: 75-90% and 10-25%), different expression of receptors (e.g. 
FcαRI and FcγRIIA/C), surface proteins (CD4 only on human macrophages) as well 
as other proteins and factors (e.g. granulysin only in humans). Furthermore, there 
are also differences of the effects of certain proteins and other factors (e.g. 
macrophage nitric oxide production induced by IFNγ and LPS (mouse) vs IFNα/β, IL-
4 and anti-CD23 (human)). These differences between mouse and human might 
explain why virtually no treatment that had a significant impact in murine models of 
sepsis worked in the following 25 clinical trials in patients suffering from sepsis 
(Unsinger et al. 2009). All these studies show the need for a small animal model that 
resembles the nature of the human immune system, and may therefore be used to 
study human specific pathogens and immune responses as well as hematopoiesis.  
In order to study human biological processes in vivo, mice need to be ‘humanized’. 
This can be done e.g. by engraftment with cells isolated from human tissue (e.g. fetal 
liver, bone marrow, thymus), peripheral blood mononuclear cells (PBMC) or CD34+ 
hematopoietic stem cells (HSC) (Shultz et al. 2007). The hematopoietic stem cells 
can be obtained from several sources: the bone marrow of adult donors (1 HSC per 
105 cells) is the classic source of stem cells. A second option is to mobilize HSC by 
injection of certain cytokines (e.g. granulocyte colony stimulating factor (G-CSF)) and 
to collect the CD34+ cells by filtering the peripheral blood of donors. Another source 
for human HSC is the umbilical cord blood, which - unlike adult peripheral blood – is 
rich in HSC. CD34+ cells can also be acquired from fetal tissues, like liver and bone 
marrow (Stem cell information NIH 2001; Laughlin 2001; Schmitz & Barrett 2002; 
Shultz et al. 2005). 
Engraftment with human cells and/or tissue is only possible in immunodeficient host 
mice, which are at least limited, or at best unable to reject xenografts.  
In 1962, the first immunodeficient mouse strain was discovered. A mutation in the 
FOXN1 gene not only resulted in hairlessness (which has given the nude mouse 
strain its name), but also in the absence of a thymus. This defect results in a lack of 
functional T cells and Ig, except IgM. They further display a weak response to T cell-
dependent antigens, but have increased amounts of NK cells. Nude mice have been 
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used for xenografts, mostly human solid tumors and tumor cells. Subsequently these 
models have been used to study the effects of various treatments and drugs on 
tumor growth and investigate tumor immunity. However nude mice have been 
replaced in most research areas by severe combined immune deficiency (SCID) 
mice (Fogh & Giovanella 1978; Caretto et al. 1989; Holub 1992; Charles River 2007). 
One of the reasons being, that nude mice do not support the growth of transplanted 
human HSC, in contrast to SCID mice (Garnick et al. 1980). 
In 1983 Bosma et al. discovered a mutation in the Prkdc (protein kinase, DNA 
activated, catalytic polypeptide) gene in CB17 mice, resulting in severe combined 
immunodeficiency (scid) (Bosma et al. 1983). A functional Prkdc gene is required for 
the activation of DNA recombinase enzyme, which in turn is essential for antigen 
receptor rearrangement. Since this mechanism is necessary for the development of 
mature T and B cells, both cell types are absent in C.B-17-scid mice (Greiner et al. 
1998). Mosier et al. were the first to proof that engraftment with human PBMC was 
possible in C.B-17-scid mice (Mosier et al. 1988). McCune and colleagues followed 
promptly and established a new model by transplanting fetal hematopoietic tissues 
(human fetal liver, thymus, spleen and lymph nodes) under the renal capsule of 
these animals (McCune et al. 1988). Also, the successful engraftment with human 
HSC in C.B-17-scid mice has been shown (Lapidot et al. 1992).  
Table 1: Research subjects using C.B-17-scid mice  
Subject Study 
Tumor studies Veronese et al. 1994 
Human stem cell phenotype and differentiation Kollman et al. 1994 
Heike et al. 1995 
Fraser et al. 1995 
McCune et al. 1996 
Human gene therapy protocols Akkina et al. 1994 
Yurasov et al. 1997 
Human T cell differentiation and function DiGiusto et al. 1996 
Roncarolo et al. 1996 
Infection of human T cells with HIV Jamieson et al. 1996 
Homing of human myeloma cells into bone marrow Urashima et al. 1997 
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Engraftment of human HSC in C.B-17-scid mice generates hu-SRC-SCID mice. SRC 
is the abbreviation of scid-repopulating cell, and characterizes a primitive human 
stem cell with the ability of multilineage repopulation of the bone marrow of irradiated 
immunodeficient mice (Larochelle et al. 1996).  
Although the C.B-17-scid mice were used extensively in various fields of research 
(table 1), and also have provided valuable results, this model has several major 
limitations. The level of engraftment of human cells in the bone marrow is quite low 
(0.5-5% of total cell number) (Lapidot et al. 1992). For some cytokines and growth 
factors there is species cross-reactivity, however others are species-specific, so that 
the human stem and progenitor cells cannot utilize those from their murine host. 
Examples for species-specific cytokines are IL-3, stem cell factor (SCF) and 
granulocyte/monocyte colony stimulating factor (GM-CSF) (Greiner et al. 1998). This 
growth factor and cytokine-deficient microenvironment contributes heavily to the 
reduced proliferation and differentiation of human hematopoietic stem cells in the 
murine host (Bock et al. 1995). However, the microenvironment of the human cells is 
not the major reason for the poor engraftment of C.B-17-scid mice. The main 
problem is the rejection of the engrafted cells. Although lacking mature T and B cells, 
these mice have an enhanced innate immune system, comprised of increased levels 
of hemolytic complement and NK cell activity compared to C.B-17 wild type mice. 
This could be a compensation mechanism for the lack of the adaptive immune 
system (Shultz et al. 1995; Greiner et al. 1998; Macciarini et al. 2005). Aside from the 
poor engraftment of human cells, the C.B-17-scid mice display ‘leakiness’. This 
phenomenon, which occurs during aging, is the spontaneous rearrangement of 
antigen receptors, leading to the generation of mature murine T and B cells (Bosma 
et al. 1988).  
Due to the leakiness and low engraftment, other immunodeficient mouse models 
were generated and investigated for engraftment of human cells and tissue. Since 
high NK cell numbers are a major factor for rejection of transplanted cells, bg/nu/xid 
mice have been generated. The beige (bg) mutation reduces the number of NK cells, 
the nude (nu) mutation prevents the development of mature T cells, and the xid 
mutation reduces the number of lymphokine activated killer (LAK) cells. Although 
these mice display higher engraftment of human colony forming units compared to 
C.B-17-scid mice, they did not prevail (Kamel-Reid & Dick 1988; Greiner et al. 1998). 
Additional models were RAG1- and RAG2-knockout mice, which are deficient for the 
V(D)J recombination activation gene (RAG) 1 and 2. Since both genes are essential 
for the V(D)J recombination in the generation of antigen receptors, both mouse 
Introduction  20 
strains lack mature T and B cells (Mombaerts et al. 1992; Shinkai et al. 1992). In the 
end, C.B-17-scid mice were considered to be the mouse strain most suitable to be 
improved by modifications in order to increase engraftment levels (Greiner et al. 
1998).  
A more robust engraftment and also long-term repopulation of human cells is 
necessary for many scientific questions. Therefore C.B-17-scid mice have been 
backcrossed with various inbred mouse strains (C3H/HeJ; C57BL/6J; C57BL/6; DBS 
and NOD). The resulting animals have been engrafted with human PBMC, to 
evaluate the best strain background for human reconstitution (Hesselton et al. 1995; 
Greiner et al. 1998). The NOD-scid mice, resulting from crossing non obese diabetic 
(NOD/Lt) with C.B-17-scid mice, have displayed the best level of engraftment (5-10x 
higher than other strains) (Hesselton et al. 1995). NOD/Lt mice are a model for 
spontaneous autoimmune T cell mediated insulin-dependent diabetes mellitus 
(IDDM) which develops at the age of 4-6 weeks (Shultz et al. 1995). These animals 
show defective T cell as well as macrophage activation, resulting in low IL-2 and IL-1 
production (Serreze & Leiter 1988). They have functional deficits in NK cells 
(Kataoka et al. 1983) and reduced monocyte/macrophage development and 
differentiation, including incomplete maturation upon IFN-γ stimulation, reduced 
proliferation, less mature phenotype, etc. (Serreze et al. 1993). Furthermore, NOD/Lt 
mice lack the complement protein C5, necessary for the formation of the membrane 
attack complex, and therefore display no complement lytic activity (Baxter & Cooke 
1993).  
In contrast to NOD/Lt, NOD-scid mice do not develop IDDM, since it is both mediated 
by and dependent on mature T cells, which are absent due to the scid mutation. 
Compared to C.B-17-scid mice, these animals show no hemolytic complement 
activity, and have a severely reduced NK cell activity, both endogenous and after 
stimulation with poly I:C. Furthermore, the NOD-scid strain is markedly less prone in 
developing ‘leakiness’. Only 10% of NOD-scid vs 90 % of C.B-17-scid mice develop 
detectable levels of immunoglobulin by 200 days of age. Furthermore NOD-scid mice 
maintain allogeneic skin grafts for several months. These findings indicate the 
absence of both mature B and T cells. These animals also display some defects of 
myeloid cells, like a significantly reduced IL-1 production upon LPS stimulation. The 
deficiencies, mostly the reduced NK cell and complement activity, explain the 
increased reconstitution of human cells compared to C.B-17-scid mice. Another 
factor, which furthers human HSC engraftment in NOD-scid mice, is the Signal-
regulatory protein alpha (SIRPA) allele expressed on the macrophages due to the 
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NOD background. Due to a polymorphism in the IgV-like domain of SIRPA, the 
protein can bind to human CD47. This not only inhibits phagocytosis and secretion of 
proinflammatory cytokines like TNF, preventing graft rejection by murine 
macrophages, but is also thought to induce signaling pathways in human HSC that 
increase their survival and engraftment levels (Takenaka et al. 2007).  
However, the increased engraftment levels come at a price. NOD-scid mice contain 
the murine leukemia provirus Emv30 in the proximal region of chromosome 11. This 
provirus is not expressed in NOD/Lt mice, but induces spontaneous thymic 
lymphomas in NOD-scid mice after 5 months and is the major cause of death in 
aging NOD-scid mice which have a median survival of only 8.5 months (Shultz et al. 
1995; Greiner et al. 1998). 
Table 2: Research subjects using NOD-scid mice 
 
Table 2 shows examples of studies where the NOD-scid model was used. Although 
this model is far superior in engraftment of human cells compared to nude and C.B-
17-scid mice, it still possesses various drawbacks. Therefore, several mouse models 
have been developed to improve the generation of a functional human immune 
system in immunocompromised mice. One approach was the knockout of the β2 
microglobulin (B2m) gene. This gene is required for MHC class I expression, and is 
essential for NK-cell development. Due to the total absence of functional NK cells in 
NOD-scid B2m-/- mice, they have moderate engraftment levels for human HSCs, 
Subject Study 
Hematopoiesis  LaRochelle et al. 1996 
Hogan et al. 1997 
Gan et al. 1997 
Leukemia Steele et al. 1997 
Appelbaum et al. 2001 
Cysticercosis Ito et al. 2001 
Gene therapy Woods et al. 2002 
Sjögren’s syndrome Cha et al. 2002 
Dengue fever Bente et al. 2005 
EBV infection and toxic shock syndrome Melkus et al. 2006 
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higher numbers of T cells and multiple human myeloid linages, although only in low 
numbers. However, like NOD-scid mice, they only develop immature human B cells, 
and due to the lack of NK cell activity, the mice develop, and die from T cell 
lymphomas faster (Christianson et al. 1997; Macchiarini et al. 2005; Shultz et al. 
2007).  
A number of additional immunodeficient mouse strains were generated, each having 
certain advantages but also disadvantages for engraftment of human tissue, lifespan, 
etc. Some strains have been based on the deficient Prkdc allele responsible for scid, 
e.g. C57BL/6-scid bg and BALB/c-scid bg, both featuring low NK cell function, but 
high levels of innate immunity resulting in low to very low engraftment with human 
HSC. Since the NOD background provides a very good basis for human cell 
engraftment, it has been used for various immunodeficient strains: NOD-scid and 
NOD-scid B2m-/- mice, described above; NOD-scid IL-3, GM-CSF, SCF transgenic 
mice, which express human hematopoietic factors, but still have low levels of human 
HSC engraftment; NOD-Rag1-/- and improved NOD-Rag1-/- Prf1-/- mice with low and 
very low NK cell activity, respectively. However, both strains display only limited 
levels of engraftment (Shultz et al. 2007). For a comprehensive review and 
references of all the immunodeficient mouse strains described above, see Shultz et 
al. 2007.  
A breakthrough in generating immunodeficient mouse strains for humanization has 
been the introduction of a targeted mutation in the IL-2RG locus (IL2rg), also called 
common γ-chain (γc). The γc is not only an essential element of IL-2/4/7/9/15 and IL-
21 receptors, but also required for signaling through these receptors. Lack or 
truncation of the γc results in seriously impaired T and B cell function and 
development and abolishes NK cell development altogether (Ito et al. 2002; Ishikawa 
et al. 2005; Shultz et al. 2007).  
Two different mutated IL2rg have been implemented into several stains by 
backcrossing. One of the IL-2RG loci (Il2rgtm1sug) produces a truncated protein, 
lacking the intracytoplasmic domain. This leads to the abrogation of all signaling 
through receptors containing the γc. The other IL-2RG locus (Il2rgtm1Wjl) is an entire 
knockout, resulting in the complete absence of a γc. Introduction of mutated IL-2R γ-
chain loci in NOD-scid mice generated NOG (NODShi.Cg-Prkdcscid Il2rgtm1sug/Jic 
[NOD/LtSz-scid IL2rg-/-] with truncated γc) and NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/Szj 
[NOD/Shi-scid IL2rg-/-] without γc) mice. It was hypothesized that the presence of the 
truncated γc could lead to the binding of human cytokines, like IL-7 to murine cells, 
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bearing the correlating receptors. The retention of human cytokines by murine cells 
would in turn disturb and reduce the development of certain human leukocytes, in 
case of IL-7 this would be T cells. This theory could help explain why NSG mice 
display higher engraftment of human CD45+ cells in spleen, bone marrow and 
thymus compared to NOG mice, although only by 10-20% (McDermott et al. 2010) 
(Shultz et al. 2007; McDermott et al. 2010). The resulting immunodeficient strains 
with Rag2-/- background are H2d-Rag2-/-IL2rg-/-, BALB/c Rag2-/-IL2rg-/-. NSG and 
NOG mice have a long lifespan of >90 weeks since there is no thymic lymphoma 
development. This is most likely because the thymocytes, which generate the 
lymphomas, require IL-7 and IL-2 receptor signaling in order to expand (Shultz et al. 
2005). There is also no sign of leakiness, even after irradiation, which generally 
enhances the sporadic development of T and B cells (Ballen et al. 2001). Due to the 
γc knockout, the strains display markedly increased engraftment levels of human 
cells (Shultz et al. 2007). Upon humanization with HSC from adult donors, NSG mice 
show 6-fold higher amounts of human CD45+ cells in the spleen, 10-fold higher in 
BM, 100-200-fold higher in thymus and >60-200-fold higher in the peripheral blood 
compared to NOD-scid mice (Shultz et al. 2005). Transplantation of HSC into NSG 
mice following irradiation results in the generation of human granulocytes, 
monocytes/macrophages, NK cells, plasmacytoid and myeloid DCs, mature T and B 
cells, and even erythrocytes and platelets (Ishikawa et al. 2005; Shultz et al. 2005; 
Shultz et al. 2007; Unsinger et al. 2009). The human T cells found in the NSG mice 
develop by progressing through the expected stages of intrathymic development 
(CD4 CD8 double-negative, CD4 CD8 double-positive and finally CD4 or CD8 single 
positive) (Shultz et al. 2005; Shultz et al. 2007). In contrast to T cells from humanized 
NOD-scid mice, T cells from NSG mice display a complex T cell receptor (TCR) 
repertoire with high levels of TCR rearrangements. They are much more abundant in 
numbers and there are also regulatory T cells (Treg) present (Shultz et al. 2005; 
Shultz et al. 2007). T cells from NSG mice display human leukocyte antigen (HLA)-
dependent cytotoxicity (killing of allogeneic lymphoblastoid cells), mount a delayed-
type hypersensitivity (DTH) response, and proliferate after stimulation. Furthermore, 
B cells can undergo class switching and generate antigen specific IgM and IgG upon 
immunization with ovalbumin (OVA) (Shultz et al. 2005; Ishikawa et al. 2005; 
Unsinger et al. 2009).  
Humanized NSG mice were used for various studies in different research fields (table 
3), and although they represent a marked improvement to previous animal models, 
there are still ways to improve this particular model for translational research.  
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Table 3: Research subjects using NOD-scid γ-chain knockout mice 
Subject Study 
Acute lymphoblastic leukemia Agliano et al. 2008 
Sepsis model Unsinger et al. 2009 
Dengue fever pathogenesis Mota & Rico-Hesse 2009  
Mota & Rico-Hesse 2011 
Malaria model Jimenez-Diaz et al. 2009 
Melanoma lung metastases Carreno et al. 2009 
ADCC against leukemia cells Ito et al. 2009 
Ovarian cancer Bankert et al. 2011 
Chemotherapy against hepatoblastoma Lieber et al. 2011 
Breast cancer model Wege et al. 2011 
GVHD model Covassin et al. 2011 
Treatment for rhabdomyosarcoma Tahan et al. 2012 
Disease progression of HIV Long & Stoddart 2012 
HIV therapy Vets et al. 2012 
Dubrovsky et al. 2012 
 
In order to further enhance the engraftment of human HSC or PBMC, the residual 
murine myeloid cells (macrophages, granulocytes and DC) should be eliminated. 
This can be achieved by treating the animals with liposome encapsulated 
dichloromethylenebisphosphonate or specific antibodies prior to transplantation with 
human cells (Shultz et al. 2007). Studies also showed that administration or 
transgenic expression of human hematopoietic growth factors and cytokines (e.g. IL-
3, SCF and GM-CSF) improves engraftment and differentiation of human HSC in 
NSG mice. Other cytokines like IL-7 facilitate the function and development of 
lymphocytes, in this case T cells (Shultz et al. 2007; Andre et al. 2010; Takagi et al. 
2012). 
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1.4 BACKGROUND ON TREATMENT OPTIONS 
 
1.4.1 LUNG MATURATION - BETAMETHASONE 
 
Liggins and Howie have been the first, who used antepartum glucocorticoid 
treatment in a clinical trial to prevent respiratory distress syndrome in premature 
infants (Liggins & Howie 1972). Before the widespread use of glucocorticoids for fetal 
lung maturation, respiratory distress syndrome (RDS) has been a main cause of 
neonatal death. RDS occurs due to inadequate production and presence of 
surfactants in the fetal lung before 32 to 34 weeks of gestation. Surfactants are 
produced by type II alveolar cells. They are composed of the surfactant proteins SP-
A, SP-B and SP-C and several lipid species, the primary lipid being 
Dipalmitoylphosphatidylcholine (DPPC). Surfactants coat the alveoli with a 
lipid/protein-monolayer, thereby reducing the surface tension to near 0 (Longo 1993). 
This is called compliance (ease of expansion of the lungs) and essential for a 
markedly reduced respiratory effort. Furthermore, surfactants help the lung 
maintaining a large alveolar surface area, where gas exchange can take place 
(Schürch et al. 1992). Therefore, lack of surfactants, occurring in premature infants, 
leads to a collapse of alveoli during expiration, and the following inspiration requires 
considerable effort. This quickly induces fatigue, leading to decreased respiratory 
effort, followed by hypoxia, cyanosis, acidosis and finally death (Purandare 2005). 
Since the 1970s, antepartum glucocorticoids are the recommended practice to 
prevent RDS and intraventricular hemorrhage (IVH) in preterm infants (NIH Consens 
Statement 1994). Studies in fetal sheep have shown that Betamethasone treatment 
markedly decreased cerebral blood flow in all brain regions except the hippocampus 
24 h, and less pronounced 48 h post injection. This effect is mediated by the 
vasoconstrictory impact of Betamethasone on fetal cerebral blood flow. This may 
explain the reduction of IVH after glucocorticoid treatment (Schwab et al. 2000).  
Meta-analysis of 18 studies confirmed that prophylactic glucocorticoids reduce 
incidence and severity of RDS, IVH and neonatal mortality of preterm infants born at 
24 to 34 weeks of gestation (Crowley 2000). The commonly utilized glucocorticoids 
are Dexamethasone or Betamethasone. They were chosen due to their long half-
lives, limited mineral corticoid activity and both also readily cross the placenta 
(Goldenberg 2002). However, since Baud et al. determined that Betamethasone is 
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more effective in reducing periventricular leukomalacia and also IVH compared to 
Dexamethasone, the better choice seems to be Betamethasone (Baud et al. 1999). 
The standard therapy regimen is 12 mg Betamethasone given twice, 24 h apart, to 
the mother (Goldenberg 2002; Peltoniemi et al. 2006).  
Although it is unknown if glucocorticoid therapy increases the maternal and/or 
neonatal infection, it is generally acknowledged, that the beneficial effect of 
preventing RDS, IVH and therefore also neonatal death outweighs the potentially 
greater risk of infection (NIH Consens Statement 1994).  
 
1.4.2 TOCOLYSIS - INDOMETHACIN 
 
Preterm delivery by definition occurs between 20 to 37 weeks of gestation. The 
preterm delivery rate in the US is about 11% and varies in Europe between 5% and 
7%. Although mortality based on prematurity decreased due to improved neonatal 
intensive care, it still remains a leading cause of death (60-80% of death of neonates 
without congenital anomalies). Preterm deliveries primarily result from spontaneous 
preterm labor (40-50%), premature rupture of membranes (25-40%) or obstetrically 
indicated preterm delivery (20-25%) (Goldenberg 2002). Even with intensive care, 
neonates born before 22 weeks of gestation are incapable of surviving. The survival 
of neonates at a gestational age of 22 weeks is rare. However, with a gestational age 
of 23 weeks, the approximate survival rate is already 25%, with 24 weeks 50%, with 
25 weeks 70% and about 80% for neonates born 26 weeks after gestation 
(Goldenberg 2002). It is evident that delaying or preventing preterm labor in the 
timeframe between a gestational age of 20 to 26 weeks greatly enhances the infants 
probability to survive. There are a number of tocolytic agents available for delaying 
time of delivery. These include Ritodrine, Terbutaline, magnesium sulfate, Nifedipine, 
Atosiban and Indomethacin. These drugs have different mechanisms of action. 
Ritodrine and Terbutaline stimulate β2 receptors, which results in an increase in 
intracellular cAMP. This inhibits the myosin light chain kinase, inducing uterine 
smooth muscle relaxation. The relaxation leads to the inhibition of uterine 
contractions and therefore temporarily arrests premature labor. Nifedipine is a 
calcium channel blocker, inhibiting calcium influx into the smooth muscle cells and 
thereby inhibiting contractions. Magnesium sulfate is a calcium antagonist, which 
also inhibits contractions and stopping premature labor. Atosiban is an oxytocin 
antagonist, which inhibits oxytocin-induced uterine contractions and thereby 
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preventing delivery (Goldenberg 2002; DeHeus 2008; Mediglyphics). Indomethacin is 
a non-steroidal anti-inflammatory drug (NSAID) that inhibits both the cyclooxygenase 
(COX)-1 and 2 (Woods et al. 2001; Sekar & Corff 2008). Both convert arachidonic 
acid into prostaglandin (PG)-G, which is quickly converted into PGH. PGH then 
serves as a precursor from which all other prostaglandins originate (Perrone et al. 
2010). COX-1 is constitutively active in most cell types and produces so called 
protective prostaglandins (PG), which preserve the integrity of the stomach lining and 
maintain normal renal function among others. COX-2 is inducible and it produces PG 
which play a role in ovulation, the birth process and inflammation. PG, especially 
PGE2, which is mostly produced by monocytes in humans, has been shown to exert 
effects on both cellular and humoral immune responses and inflammation (Goodwin 
et al. 1978; Goodwin & Ceuppens 1983; Vane et al. 1998; Thuresson et al. 2001; 
Suleyman et al. 2010). The role of PGs in labor is stimulation of myometrial 
contractions, cervical softening, and induction of enhanced levels of myometrial gap 
junctions, which increase intracellular calcium levels and thereby enhance 
myometrial activity (Husselein 1984; Riemersma et al. 1998). As with the above 
mentioned tocolytics, studies using Indomethacin to block labor show very 
contradicting results regarding efficacy and side effects. However, Loe et al. 
performed a meta-analysis of 28 studies, and concluded that Indomethacin therapy 
did not significantly increase the rate of IVH, bronchopulmonary dysplasia, premature 
closure of the ductus arteriosus and perinatal mortality, which were all side effects, 
mentioned in other studies. But he also did not exclude adverse outcomes, since the 
limited statistical power of the 28 studies did not allow that (Loe et al. 2005). Suarez 
et al. described that most studies claiming that Indomethacin increases the risk of 
IVH use the drug as a second line tocolytic, when the first one fails. This procedure 
increases the risk of IVH. In addition, animal studies showed that Indomethacin even 
protects the fetus from IVH (Suarez et al. 2001). Combining Indomethacin with 
another tocolytic also increases the risk for necrotizing enterocolitis in infants, 
whereas the use of Indomethacin alone does not (Parilla et al. 2000). Other studies 
indicate that in 10-50% of fetuses exposed to Indomethacin, premature closure of the 
ductus arteriosus occurs. This can lead to pulmonary hypertension and even heart 
failure in the fetus, and mostly happens when the drug is administered for more than 
48 h and at higher gestational age (>32 weeks) (Goldenberg 2002; Giles 2007; 
Perrone et al. 2010). Since prostaglandins, especially PGI2 and PGE2 are important 
for regulation of kidney function (e.g. increase of renal blood flow, salt and water 
excretion), renal dysfunction such as anuria, increased serum creatinine 
concentrations and even renal microscopic lesions have been reported after prenatal 
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Indomethacin exposure (Norton et al. 1998; Goldenberg et al. 2002). Although renal 
dysfunction is a serious side effect, Indomethacin does not seem to cause negative 
long-term effects. A study on neonates treated with Indomethacin for patent ductus 
arteriosus did show increased levels of serum creatinine, decreased glomerular 
filtration rate and 24% of infants even displayed acute renal failure on day 2 and 7 
upon Indomethacin treatment. However, after 30 days the renal function was normal 
in all infants (Akima et al. 2004).  
 
1.5 AIM 
 
The aim of this study was to determine the effect of Betamethasone and 
Indomethacin treatment on the human neonatal immune system during an ongoing 
infection. As described above, Betamethasone is the standard treatment for 
promoting fetal lung maturation of premature infants in the clinic. Indomethacin is one 
of the tocolytics, which are routinely used to prevent premature birth in the clinic. 
Although, both drugs are routinely used in the clinic, not much is known about their 
effect on the neonate in regards of organ damage, or their effect on the neonatal 
immune system and disease progression. Therefore, I generated a new infection 
model using humanized mice, to mimic the naïve human neonatal immune system 
and subsequently tested both treatment options. Humanized NSG mice were 
infected with GBS, animals were treated with Betamethasone or Indomethacin and 
the effects of both drugs on clearance of live bacteria, migration and proliferation of 
immune cell populations, immune cell function (cytokine and nitric oxide production) 
and organ damage was analyzed. 
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2  MATERIAL & METHODS 
2.1 METHODS 
2.1.1 ANIMALS 
 
The animals used for this study were NOD.Cg-Prkdcscid Il2rgtm1Wjl/Sz (NOD-scid 
IL2Rnull, NSG) mice, which were obtained from Jackson Laboratories, USA. Mice 
were kept and bred in a specific pathogen free animal facility at the University 
Hospital Regensburg.  
 
2.1.2 HUMANIZATION OF MICE 
 
Neonatal mice (0-2 days old) were irradiated with 1 gray. This process is called 
conditioning and necessary to clear stem cell niches in the bone marrow, which can 
subsequently be settled by human hematopoietic stem cells (HSC). These human 
CD34+ stem cells were purified from human cord blood as follows:  
Fresh human cord blood, containing citrate to prevent coagulation, was mixed with 
PBS in a ratio 1:1. The diluted blood is carefully layered on 15 ml Pancol (Pan 
Biotech, Aidenbach, Germany) in a 50 ml Falcon tube (Sarstedt, Nümbrecht, 
Germany) and centrifuged at 600 rcf, room temperature (RT) for 30 min. After density 
gradient centrifugation, the following layers are visible from top to bottom: the plasma 
layer, the so-called buffy coat (containing mono-nuclear cells (MNC) and platelets), 
the Pancol layer, and a pellet of erythrocytes and granulocytes. The MNC could 
easily be harvested from the buffy coat using a 5 ml pipette (Sarstedt). MNC were 
transferred into 25 ml PBS + 2 mM EDTA to prevent clotting and to dilute Pancol 
which can be harmful for MNC when exposed to for a longer period of time. After 
centrifugation for 10 min at 300 rcf, 4°C, MNC were resuspended in 5 ml PBS + 2 
mM EDTA and counted. Cell suspension was diluted 1:100 with Trypan blue solution 
(Sigma-Aldrich) and counted using a Neubauer counting chamber (HBG Precicolor, 
Giessen, Germany). For purification of human CD34+ hematopoietic stem cells from 
cord blood MNC, MACS cell separation (Miltenyi Biotech, Bergisch Gladbach, 
Germany) was utilized. The cell suspension was centrifuged, supernatant was 
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removed and MNC were resuspended in MACS buffer (table 8) (150 µl/108 MNC). 
After adding CD34 Microbeads (Miltenyi Biotech) and MACS Fc Block (Miltenyi 
Biotech) (50 µl beads and block/108 cells), cells were incubated 30 min at 4°C. Then 
MNC were washed with MACS buffer (10 ml / 108 cells), centrifuged for 10 min at 
300 rcf, 4°C, supernatant was removed, and labeled MNC were resuspended in 
MACS buffer (250 µl/108 cells). A MACS MS Separation Column (Miltenyi Biotech) 
was placed in the magnetic field of a MACS Separator (Miltenyi Biotech) and rinsed 
with 500 µl MACS buffer. Labeled MNC suspension was applied over a 40 µm cell 
strainer and passed through the column. The effluent was reapplied onto the column 
and passed through a second time to increase yield. Subsequently, the column was 
washed 3x with 500 µl MACS buffer. The column was removed from the Separator 
and placed on a 15 ml Falcon tube (Sarstedt). Cells were flushed out by applying 1 
ml MACS buffer and pushing the plunger into the column. In order to increase the 
purity of the magnetically labeled CD34+ stem cells, they were passed over a second 
column (as described above). MNC in the effluent were frozen and stored (see 2.9). 
After purification, 10 µl of the cell suspension were stained (table 8 staining C) for 
flow cytometric analysis to determine purity. Stem cells were counted by diluting 10 
µl of the cell suspension 1:10 with trypan blue solution. The remaining cells were 
centrifuged at 300 rcf, 4°C for 10 min, and resuspended in RPMI 1640 medium (Pan 
Biotech, Aidenbach, Germany) (2x105 stem cells per 50 µl).   
Purified CD34+ stem cells were transplanted into previously conditioned NSG 
neonates. 50 µl cell suspensions, containing 2x105 cells, were injected 
intrahepatically using a BD SafetyGlide Insulin syringe (BD Biosciences, Franklin 
Lakes, USA). The CD34+ human hematopoietic stem cells generated a complete 
human immune system in the transplanted, humanized mice. After approximately 6 
weeks, when the generation of the human immune system was completed, 
peripheral blood (pb) was taken from each mouse and analyzed using flow cytometry 
(table 4, staining T and M) to determine the level of reconstitution. 
 
2.1.3 GROWING AND QUANTIFYING BACTERIA FOR INFECTION 
 
Stock cultures of GBS were prepared using the Mikrobank Bacterial Storage System 
(Prolab Diagnostics, Richmond Hill, Canada) according to manufacturer’s protocol. 
GBS (reference stain ATCC 13813 received from Department of Microbiology, 
University Hospital Regensburg) were plated on blood agar plates and grown 
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overnight at 37°C. Subsequently, bacteria were scraped off the plate using an 
inoculation loop and used to inoculate cryopreservative in Mikrobank vials containing 
plastic beads. Vials were inverted 4–5 times to distribute the bacteria on the beads. 
Cryopreservative was aspirated and vials containing inoculated beads were stored at 
-80 °C.  
In order to grow GBS for infection of animals or for in vitro experiments, 2 blood agar 
plates were inoculated with one inoculated bead each and incubated overnight at 
37°C. Bacteria were scraped off the plate, transferred into 1 ml PBS and vortexed 
vigorously. GBS suspension was diluted with PBS and adjusted to an optical density 
(OD) of 0.400 using a Nano Photometer (Implen, Munich, Germany). The bacteria 
suspension was serially diluted starting at 10-1 down to 10-6. Dilutions 10-4, 10-5 and 
10-6 were plated on blood agar plates and incubated at 37°C overnight. Colonies on 
plates were counted and calculated to ensure that the suspension contained 
appropriate amount of GBS.  
 
2.1.4 INFECTION AND TREATMENT OF ANIMALS 
 
Humanized or non-humanized NSG mice were infected with different doses of GBS. 
For determining appropriate infectious doses for humanized mice, the animals were 
injected with different amounts of live bacteria (1x105, 5x105, 1x106, 1x107, 5x107, 
1x108). For each dose, the bacteria suspension was adjusted with PBS, so that 1 ml 
PBS contained the appropriate amount of live bacteria. Each mouse was then 
infected by injecting 1 ml of GBS suspension intraperitoneally using a Plastipak 1 ml 
syringe (BD, USA) in combination with a 27 G Microlance 3 needle (BD Biosciences). 
Animals that were infected with 107 GBS for 24 h (short term infection) received 
either vehicle control (PBS) or 5 mg/kg Betamethasone (Essex pharma, Munich, 
Germany) intraperitoneally 3 h post infection. Mice that obtained 106 GBS and were 
killed either 3 d (intermediate infection) or 7 d (long term infection) after infection 
received either vehicle control (PBS), 5 mg/kg Betamethasone or 3 mg/kg 
Indomethacin (Euro OTC Pharma, Bönen, Germany) 24 h as well as 48 h post 
infection. 
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2.1.5 PREPARATION OF BLOOD, SINGE CELL SUSPENSIONS AND TISSUE 
FROM MICE 
 
Mice were anesthetized and blood samples were taken retrobulbarly. For flow 
cytometric analysis, 100 µl pb were mixed with 20 µl 0.5 M EDTA. The remaining pb 
was collected in a 1.5 ml reaction tube and allowed to clot at 4°C, to obtain serum for 
cytokine analysis (see 2.18). After bleeding, mice were killed by cervical dislocation. 
Using a 10 ml BD Discardit II syringe (BD Biosciences) in combination with a 22G BD 
Microlance needle (BD Biosciences), the peritoneum was rinsed with 10 ml FACS 
buffer to obtain peritoneal lavage containing peritoneal exudate cells (PEC).  
One femur, spleen, two kidneys, liver, mesenteric lymph nodes (mLN), lung and 
brain were removed and placed in PBS (Pan Biotech). Approximately one fourth of 
the spleen and liver, half of a kidney and the brain and a whole mLN were embedded 
for histological analysis (see 2.13-15). The remaining part of the organ was weighted, 
passed through a 40 µm cell strainer (BD Biosciences) using a 2 ml BD Discardit II 
syringe plunger (BD Biosciences), and washed 2x with 10 ml PBS. The ends of the 
femur were clipped off and the bones were rinsed with RPMI 1640 medium using a 5 
ml BD Discardit II syringe (BD Biosciences) in combination with a 27G BD 
Microlance needle (BD Biosciences). The extracted bone marrow was passed 
through a 40 µm cell strainer (BD Biosciences) using a 2 ml BD Discardit II syringe 
plunger (BD Biosciences). Subsequently, 200 µl of the resulting single cell 
suspensions were removed and kept for colony forming unit (CFU) detection (see 
2.7). The remaining single cell suspensions were centrifuged at 300 rcf, 4°C for 10 
min. Supernatants were discarded and the cells were resuspended in residual PBS 
and counted. Afterwards, 106 cells were stained for flow cytometric analysis (see 
2.8).  
 
2.1.6 PERCOLL CELL SEPARATION  
 
In order to be able to conduct flow cytometric analysis of single cell suspensions of 
lung and liver, a density gradient cell separation was conducted to separate 
leukocytes from lung epithelial cells or hepatocytes, respectively. 100% Percoll (GE 
Healthcare, Uppsala, Sweden) was diluted with RPMI 1640 medium to 70% and 40% 
Percoll. Samples of single cell suspensions of liver and lung were centrifuged at 300 
rcf, 4°C for 10 min, and supernatant was discarded. Each sample was resuspended 
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in 5 ml 40% Percoll and carefully underlayed with 6 ml 70% Percoll using a glass 
Pasteur pipette (Brand, Wertheim, Germany). This Percoll gradient was centrifuged 
at 1000 rcf, 20°C for 20 min. Due to density separation, the following layers were 
generated: An upper band, containing almost exclusively epithelial cells or 
hepatocytes, respectively, a middle layer containing few cells (mixed population of 
MNC) and a lower band, containing the majority of MNC. The upper band was 
removed completely. Both middle and lower bands were transferred into a new 15 ml 
Falcon tube containing 5 ml PBS. Cells were centrifuged at 300 rcf, 4°C for 10 min, 
supernatant was removed, cells resuspended in residual PBS and counted.  
 
2.1.7 DETECTION OF COLONY FORMING UNITS IN VARIOUS ORGANS 
 
In order to detect live bacteria (CFU) peritoneal lavage (PEL) and single cell 
suspensions of bone marrow (BM) (from femur), spleen, kidney, liver, lung and brain 
were diluted and plated on blood agar plates. PEL and single cell suspensions were 
serially diluted from 100 to 10-4 by mixing 100 µl of each sample with 900 µl PBS. 
Each dilution was subsequently plated on blood agar plates and incubated over night 
at 37°C. Bacteria colonies were counted the next day, and the number of GBS per g 
organ (or per ml for PEL and BM) was calculated using the following formula:  
 
 
2.1.8 STAINING FOR FLOW CYTOMETRY 
 
First, 106 cells of single cell suspensions from BM, mLN, spleen, PEL, purified liver 
and lung (see 2.5,6) were adjusted to 100µl using FACS buffer (table 8). These cell 
suspensions or 100µl pb respectively, were incubated with 2 µl human serum for 15 
min to block unspecific binding sites. Subsequently, cells were incubated with 
antibodies according to the manufacturer’s protocol (dilutions see table 5) for 45 min 
at 4°C in the dark. Subsequently, erythrocytes in the samples of spleen, BM, liver, 
lung and pb were lysed using a 1:10 dilution of BD FACS Lysing Solution (BD 
Biosciences) with deionized H2O for 10 min in the dark. 2 ml FACS buffer were 
applied to each sample followed by 10 min centrifugation at 300 rcf, 4°C, and 
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supernatant was discarded. For FACS staining M and T 0.06 µg (0.3 µl) Streptavidin 
APC-Cy7 (FITC) was applied for 15 min. Samples were washed with 2 ml FACS 
buffer, centrifuged at 300 rcf, 4°C for 10 min, and supernatant was removed. Finally, 
labeled cells were resuspended in residual buffer in FACS tube by vortexing and 
analyzed using a BD LSR II Flow Cytometer (BD Biosciences).  
For analysis of FACS data, BD FACSDiva software (BD Biosciences) was used.  
Table 4: FACS stainings 
Antibody stainings 
staining FITC PE PerCP APC Pe-Cy7 APC-Cy7 
T CD4 CD19 CD3 CD8 CD45 RA CD27 biotin 
M  CD66 CD33 CD45 HLA-DR CD80 biotin 
C CD3 CD34 CD33 CD56   
V CD3 CD66 CD33 CD56 CD19  
K  CD86 CD33 CD45   
Isotype controls 
Iso T CD4 CD19 CD3 IgG1 IgG2b IgG1 biotin 
Iso M  IgG2b CD33 CD45 IgG2 IgG1 biotin 
Iso C 
no isotype 
control 
necessary 
     
Iso V 
no isotype 
control 
necessary 
     
Iso K  IgG2b CD33 CD45   
 
2.1.9 FREEZING OF MNC 
 
MNC were centrifuged at 300 rcf, 4°C for 10 min. Supernatant was removed and 
cells were resuspended in 800 µl RPMI 1640 medium. MNC were transferred into a 2 
ml Cryo Tube (Nunc, Wiesbaden, Germany) and mixed with 800µl cold freezing 
medium (2x) (table 8). Cryo tubes were immediately put into Nalgene Cryo 1°C 
Freezing Container (Nalgene, Penfield, USA) and stored at -80°C overnight. Cryo 
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tubes were transferred into gaseous phase of liquid nitrogen for long term storage at 
-178 to -150°C.  
 
2.1.10 IN VITRO DIFFERENTIATION OF MONOCYTES AND SUBSEQUENT 
STIMULATION 
 
Humanized mice were anesthetized and killed by cervical dislocation. Femurs and 
tibias were surgically removed and placed in cold RPMI 1640 medium. The ends of 
the femurs and tibias were clipped off and single cell suspensions were prepared as 
described above (see 2.5). The resulting single cell suspensions of bone marrow 
derived cells (BMDC) were counted by diluting 10 µl 1:100 with Trypan blue solution. 
BMDC were seeded at a density of 5x105 cells/cm2 in Falcon 6 well-plates (BD 
Biosciences), and cultivated in Macrophage SFM (Invitrogen, Carlsbad, USA) + 50 
ng/ml M-CSF (R&D Systems, Minneapolis, USA). Medium was changed after 24 h 
and again after 3 d to avoid activation of the macrophages. After cultivation of BMDC 
7 d under these conditions, the monocytes differentiated into bone marrow derived 
macrophages (BMDM). They were subsequently stimulated with 100 ng/ml LPS and 
1 µg CpG (Metabion, Martinsried, Germany) for 24 h. To determine their ability to 
differentiate and develop a mature/activated phenotype, the cells were analyzed 
using flow cytometry (table 4, staining K) and their phenotype was inspected 
microscopically. 
 
2.1.11 RESTIMULATION OF PEC FROM INFECTED HUMANIZED MICE 
 
Humanized mice were infected with 107 GBS for 24 h. Afterwards, PEC were 
extracted using peritoneal lavage and counted. 106 cells were seeded in 24 Multiwell 
plates (BD, USA). Cells from uninfected mice (control), infected mice treated with 
PBS (PBS) and infected mice treated with Betamethasone (BETA) were either 
incubated in RPMI 1640 Glutamax (Invitrogen, Carlsbad, USA) + 10% FBS (Pan 
Biotech) alone (-) or restimulated with Medium containing 107 live GBS (+). After 1 h 
at 37°C, plates were spun down (300 rcf, 4°C for 10 min) and medium was 
completely removed and stored at -80°C for nitrite measurement (see 2.17). One ml 
fresh RPMI Glutamax + 10% FBS, containing 0.1 mg/ml Gentamicin (Sigma-Aldrich, 
Taufkirchen, Germany) was applied to each well. After incubating the PEC for 24 h in 
Material & Methods  36 
total, plates were spun down (300 rcf, 4°C for 10 min), medium was removed for 
nitrite measurement. 
 
2.1.12 CLEARANCE AND SURVIVAL OF CORD-BLOOD DERIVED MNC 
 
MNC were extracted from fresh cord blood as described above (see 2.2) and 
counted. 106 cells were seeded in 24 Multiwell plates (BD Biosciences) each 
containing 1 ml RPMI 1640 Glutamax (Invitrogen) + 10% FBS (Pan Biotech). To test 
the effect of drugs on clearance of bacteria, either PBS (vehicle control), 1 µg/ml 
Betamethasone or 1 µg/ml Indomethacin were added before applying 107 GBS to 
each well (batch A). Samples were incubated at 37°C for 4 h. To analyze the 
influence of both drugs on MNC cultured with GBS for 24 h and 48 h, 106 cells were 
incubated with 105 live GBS and Chloramphenicol (2.5 µg/ml) was applied to 
suppress bacterial growth (batch B). As internal control GBS without MNC were 
incubated as described for batch A for 4 h (batch C). As second internal control MNC 
were also incubated without GBS as described for batch A for 4h, 24 h and 48 h 
(batch D). After incubation, clearance of bacteria (batch A and B) and survival of 
GBS (Batch C) were determined by plating 10-4, 10-5 and 10-6 dilutions of each well 
on blood agar plates, incubating them overnight at 37°C and counting them.  
To determine the effect of treatment together with bacteria (batch A and B) or 
treatment alone (batch D) on survival of MNC, cells from each well were counted and 
analyzed using flow cytometry. Therefore, MNC were resuspended in each well by 
pipetting up and down, before transferring them into a 2 ml reaction tube (Sarstedt, 
Germany). Then, adherent cells were collected by adding 500 µl PBS and scraping 
them off using a cell scraper (Sarstedt). Cells were counted, centrifuged at 300 rcf, 
4°C for 10 min, supernatant was removed and cells were resuspended in residual 
medium and stained for FACS analysis (table 4, stain V). 
 
2.1.13 PREPARATION AND SECTIONING OF PARAFFIN-EMBEDDED 
TISSUE SAMPLES 
 
Tissue samples of spleen, kidney, liver, mLN, lung and brain were put into Rotilabo-
embedding cassettes (Carl Roth, Karlsruhe, Germany) and incubated in 5% 
paraformaldehyde.  
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The tissue samples were dehydrated by transferring them sequentially in 30%, 50%, 
70%, 80%, 90%, 95% and 100% ethanol (EtOH) (J.T. Baker, Griesheim, Germany) 
for 2 h each. In order to ensure that all water is substituted with EtOH, the samples 
were put into an additional 100% EtOH solution. Subsequently tissue samples were 
cleared by incubating them 3x in xylol (Merck, Darmstadt, Germany) for 1h. Tissues 
were placed in melted paraffin (56–58°C) for 1.5 h and subsequently transferred into 
a fresh container containing melted paraffin for additional 1.5 h to ensure that tissue 
samples were completely infiltrated with paraffin. After the infiltration, the samples 
were placed in an embedding mold and grouted with melted paraffin to form a block. 
These paraffin-tissue blocks were allowed to cool and stored at RT until sectioning.  
Paraffin-tissue blocks were first trimmed to an optimal cutting surface and then 4 µm 
sections were prepared using a Leica RM2145 microtome (Leica, Wetzlar, Germany) 
according to manufacturer’s protocol. Sections were cut and placed in a warm (42°C) 
HI1210 water bath (Leica) and fished out using Superfrost Plus microscope slides 
(Menzel, Braunschweig, Germany). Sections were air dried and subsequently used 
for immunohistochemistry and Hematoxylin & Eosin (H&E) staining.  
 
2.1.14 IMMUNOHISTOCHEMISTRY OF PARAFFIN SECTIONS 
 
Paraffin sections were deparaffinized by incubating them 2x 10 min in xylol. Sections 
were pretreated by incubation in 0.1 M citrate buffer, pH 7.3 (table 8) and heating 
them 30 min in a microwave at 320 W. For immunostaining the streptavidin–biotin–
peroxidase complex method together with 3,3’-diaminobenzidine as chromogen was 
used. The staining was performed with a Ventana Nexes autostainer (Ventana, 
Tucson, USA) in combination with an iView DAB detection kit (Ventana) according to 
manufacturer’s protocol. For detection the following antibodies were used: anti-
CD45/LCA (Dako, Glostrup, Denmark) to stain human leukocytes, anti-CD3 (Thermo 
Scientific, Fremont, USA) to stain human T cells, anti-79a (Dako) to stain human B-
cells and anti-CD68 (Dako) for staining human macrophages. Sections were 
analyzed using a Zeiss Axio Imager M1 (Zeiss, Wetzlar, Germany). 
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2.1.15 HEMATOXYLIN & EOSIN STAINING 
 
Sections were fixed onto microscope slides by incubating them in acetone for 5 min 
at -20°C. Sections were air dried for 5 min at RT and rehydrated by incubation the 
sections 2x 1 min in 99% EtOH, 1 min in 96% EtOH and finally 1 min in 70% EtOH. 
Sections were incubated for 20 sec in Hematoxylin (Merck, Darmstadt, Germany) to 
stain the nuclei and subsequently washed 10 min in H2O, before incubating them 20 
sec with eosin (Carl Roth) to counterstain eosinophilic structures (mostly cytoplasm). 
Sections were washed again for 10 min in H2O before dehydrating them using EtOH. 
Therefore sections were incubated 1 min in 70% EtOH, 1 min in 96% EtOH and 2x 1 
min in 99% EtOH before submerging them in xylol. For mounting, the sections were 
taken out of the xylol and mounted using Entellan (Merck). Afterwards sections were 
air-dried and analyzed using a Zeiss Axio Imager M1 (Zeiss). 
 
2.1.16 CYTOSPIN AND STAINING OF PEC 
 
PEC from PEL (see 2.5) were counted (dilution 1:10) and adjust 2x105 cells with 
RPMI 1640 medium (Pan Biotech) + 10% FCS (Pan Biotech) to a total volume of 200 
µl. Superfrost Plus microscope slides (Menzel) were mounted with Shandon paper 
card (Thermo Scientific) and Shandon Cytofunnel (Thermo Scientific) and held 
together with Shandon Cytoclip (Thermo Scientific). Samples were applied on 
Cytofunnels and centrifuged for 6 min at 600 rpm, RT in a Shandon Cytospin 4 
Cytocentrifuge (Thermo Scientific) and air dried at RT.  
For staining of cytospins a Diff-Quick Staining Kit (Medion Diagnostics, Düdingen, 
Switzerland) was utilized. The first step of staining was fixation of cytospins by 
immersing slide for 10 sec in Diff-Quick Fixative. Cytospins were transferred into Diff-
Quick Solution 1, containing Eosin, for 20 sec. Subsequently slides were immersed 
in Diff-Quick Solution 2, containing Thiazine, for 20 sec before rinsing them gently 
with distilled water. Slides were blotted and air dried at RT before analyzing them 
using a Zeiss Axio Imager M1 (Zeiss).  
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2.1.17 ASSAY FOR MEASURING NITRITE ACCUMULATION (NO 
PRODUCTION) 
 
For measuring NO production of myeloid cells in vitro, nitrite accumulation in PEC 
supernatant of GBS infected humanized mice was measured after restimulation of 
cells with GBS (see 2.11). First, Griess reagent was prepared by mixing Griess 
solution A (table 8) and B (table 8) 1:1. For the standard curve, 10 mM NaNO2 stock 
solution (table 8) was diluted to 100 µM using ddH2O. The resulting 100 µM NaNO2 
solution was serially diluted 1:2 (6x) down to 1.56 µM using RPMI 1640. From each 
dilution 100 µl were applied onto a 96 well plate (BD Biosciences) in triplicate. Also 
100 µl of RPMI 1640 were applied in triplicate as blank. Supernatant samples were 
applied (100 µl in triplicate). Afterwards, 100 µl Griess reagent were added to each 
well and the OD was measured at 550 nm using an Emax Endpoint ELISA 
Microplate Reader (Molecular devices, Sunnyvale, USA). 
 
2.1.18 CYTOKINE DETECTION 
 
In order to determine cytokine production of human leukocytes in humanized mice, 
animals were bled retrobulbarly. The blood was allowed to clot at 4°C for 30 min and 
subsequently centrifuged at 3000 rcf, 4°C for 10 min. Serum was removed and 
centrifuged again at 10000 rcf, 4°C for 10 min to pellet contaminating cells and 
debris. Pure serum was removed and stored at -80°C until cytokine analysis.  
Serum samples were sent to Multimetrix, Regensburg, Germany for analysis. There 
a multiplex cytokine analysis was conducted, analyzing the serum cytokine levels of 
IFNγ, TNF, IL-1β, IL-6, IL-8 and IL-10.  
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2.2 MATERIALS 
 
Table 5: Antibodies for flow cytometry 
Antibody Fluorochr. Clone Isotype Manufacturer Dil.  
      
anti-human CD19 Pe HIB19 mouse IgG1,  BD Biosciences 1:20 
anti-human CD27 Biotin 0323 mouse IgG1,  
eBioscience, 
San Diego, USA 
1:50 
anti-human CD3 FITC UCHT1 mouse IgG1,  BD Biosciences 1:20 
anti-human CD3 PerCP-Cy5.5 OKT3 mouse IgG2a,  eBioscience 1:20 
anti-human CD33 PerCP-Cy5.5 P67.6 IgG1 BD Biosciences 1:20 
anti-human CD34 Pe 581/CD34 mouse IgG1,  BD Biosciences 1:20 
anti-human CD4 FITC SK3 IgG1 BD Biosciences 1:20 
anti-human CD45 APC HI30 mouse IgG1,  BD Biosciences 1:20 
anti-human CD45RA Pe-Cy7 HI100 mouse IgG2b,  eBioscience 1:50 
anti-human CD56 APC B159 mouse IgG1,  BD Biosciences 1:20 
anti-human CD66 Pe B1.1/CD66 mouse IgG2a,  BD Biosciences 1:20 
anti-human CD8a APC HIT8a mouse IgG1,  
Biolegend, San 
Diego, USA 
1:20 
anti-human CD80 Biotin 2D10.4 mouse IgG1,  eBioscience 1:50 
anti-human CD86  Pe IT2,2 mouse IgG2b,  eBioscience 1:20 
anti-human HLA-DR  Pe- Cy7 LN3 mouse IgG2b,  eBioscience 1:50 
Streptavidin APC-Cy7   BD Biosciences 1:333 
 
Table 6: Isotype controls for flow cytometry (Dilution see Table 5) 
Antibody Fluorochrome Clone Isotype Manufacturer 
     
mouse IgG1 APC  mouse IgG1,  eBioscience 
mouse IgG1 Biotin  mouse IgG1,  eBioscience 
mouse IgG1 Pe MOPC-21 mouse IgG1,  Biolegend 
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Antibody Fluorochrome Clone Isotype Manufacturer 
     
mouse IgG1 Pe-Cy7  mouse IgG1,  eBioscience 
mouse IgG1 PE-Cy5.5  mouse IgG1,  eBioscience 
mouse IgG2b Pe MPC-11 mouse IgG2b,  Biolegend 
mouse IgG2b Pe-Cy7  mouse IgG2b,  eBioscience 
 
Table 7: Antibodies for histology 
Antibody Clone Manufacturer Dilution 
   
anti-human CD3 SP Thermo Scientific, Fremont, USA 1:300 
anti-human CD45 2B11-PD7/26 Dako, Glostrup, Denmark 1:600 
anti-human CD68 P6M1 Dako, Glostrup, Denmark 1:100 
anti-human CD79a JCB117 Dako, Glostrup, Denmark 1:20 
 
Table 8: Buffers, Solutions and Media 
Buffers, Solutions and Media Application Composition 
   
Acid-Citrate-Dextrose (ACD) Cell culture 37 mM C6H8O7.H2O  
75 mM Na3C6H5O7.2H2O 
0,12 M C6H12O6 
Ammonium-Chloride-Potassium 
(ACK) lysis buffer 
Miscellaneous 0,15 M NH4Cl 
10 mM KHCO3 
0,1 mM EDTA 
in ddH2O 
BD FACS Lysing Solution 1x Miscellaneous 10 % BD FACS Lysing Solution 10x  
in ddH2O 
Blood agar plates Miscellaneous 4 % (w/v) Columbia Agar (Merck) 
8 % defibrinated sheep blood 
in ddH2O 
Citrate buffer (0.1 M; pH 7.3)  Histology 0.1 M  Na3C6H5O7.2H2O 
in ddH2O 
adjust pH value to 7.3 with NaOH 
PBS (phosphate buffered saline 
w/o Ca &Mg) 
Miscellaneous PAA, Pasching, Austria 
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Table 9: Chemicals, Reagents and Kits 
Chemicals and Reagents Application Manufacturer 
   
2-Mercaptoethanol  Cell culture Sigma-Aldrich, Taufkirchen, Germany 
2-Propanol  Miscellaneous Merck, Darmstadt, Germany 
Buffers, Solutions and Media Application Composition 
   
EDTA stock solution  
(0,5 M pH 7.9) 
Miscellaneous 0.5 M EDTA 
adjust pH value to 7.9 with NaOH 
FACS buffer Flow cytometry 2 % (v/v) FCS 
2 mM EDTA 
in PBS 
Freezing medium (2x) Cell culture 20 % (v/v) DMSO 
10 % (v/v) FCS 
25 % (v/v) Deltadex 40 
  5 % (v/v) ACD 
40 % (v/v) RPMI medium 
Griess solution A Measuring Nitrite 1 % (w/v) C6H8N2O2S 
5 % (v/v) H3PO4 
in ddH2O 
Griess solution B Measuring Nitrite 0,1 % (w/v) C10H7NHCH2CH2NH2.2HCl 
in ddH2O 
MACS buffer Cell separation 0.5 % (w/v) BSA 
2 mM EDTA 
in PBS 
NaNO2 stock solution Measuring Nitrite 10 mM NaNO2 in ddH2O 
Paraformaldehyde (PFA) 4% Flow cytometry 4 % (v/v) PFA 
2.5 mM Ba(OH)2 
0.4 mM CaCl2 
50 mM C12H22O11 
0.1 M NaH2PO4 
in ddH2O 
PBS (10x) 
 
Miscellaneous 1.5 M NaCl  
83 mM Na2HPO4 
17 mM NaH2PO4 (pH 7.4) 
in ddH2O 
Percoll (100 %) Cell separation 10 % (v/v) PBS (10x) 
90 % (v/v) Percoll (GE Healthcare) 
RPMI + 10% FCS Cells culture 10 % (v/v) FCS (Pan Biotech) in  
RPMI 1640 Glutamax (Invitrogen) 
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Chemicals and Reagents Application Manufacturer 
   
Ba(OH)2 (Barium hydroxide) PFA Merck, Darmstadt, Germany 
Bovine serum albumin (BSA) MACS Sigma-Aldrich, Taufkirchen, Germany 
C10H7NHCH2CH2NH2.2HCl       
(2-(1-Naphthylamino)ethylamine 
dihydrochloride) 
Measuring Nitrite Sigma-Aldrich, Taufkirchen, Germany 
C6H8N2O2S (Sulfanilamide) Measuring Nitrite Merck, Darmstadt, Germany 
C12H22O11 (Sucrose) PFA Sigma-Aldrich, Taufkirchen, Germany 
C6H12O6 (Dextrose) ACD Serva, Heidelberg, Germany 
C6H8O7.H2O (Citric acid) ACD  Merck, Darmstadt, Germany 
CaCl2 (Calcium chloride) PFA Merck, Darmstadt, Germany 
CD34 Micro Bead Kit MACS Miltenyi Biotech, Bergisch Gladbach, 
Germany 
Celestan 4 mg (Betamethasone) Miscellaneous Essex pharma, Munich, Germany 
CpG-1648 odn In vitro stimulation Metabion, Martinsried, Germany 
Deltadex 40 Freezing of cells Deltaselect, Munich, Germany 
Diff-Quick Staining Kit Diff-quick staining Medion Diagnostics, Düdingen, 
Switzerland 
Dimethyl sulfoxide (DMSO) Freezing of cells Applichem, Gatersleben, Germany 
Eosin G (0,5%) Histology Carl Roth, Karlsruhe, Germany 
Entellan Histology Merck, Darmstadt, Germany 
Ethanol (100%) Miscellaneous J.T. Baker, Griesheim, Germany 
Ethylenediaminetetraacetic acid 
(EDTA) 
Miscellaneous Applichem, Gatersleben, Germany 
Fetal bovine serum (FBS)  Miscellaneous Pan Biotech, Aidenbach, Germany 
Gentamicin 50 mg/ml Restimulation Sigma-Aldrich, Taufkirchen, Germany 
Hematoxylin Histology Carl Roth, Karlsruhe, Germany 
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Chemicals and Reagents Application Manufacturer 
   
HCl 37% pH adjustment Merck, Darmstadt, Germany 
H3PO4 (Phosphoric acid) Measuring Nitrite Merck, Darmstadt, Germany 
Indomethacin (5g) Miscellaneous Euro OTC Pharma, Bönen, Germany 
iView DAB detection kit Histology Ventana, Tucson, USA 
KHCO3 (Potassium bicarbonate) ACK lysis Roth, Karlsruhe, Germany 
Lipopolysaccharides from 
Escherichia coli 0127:B8 (LPS) 
Cell culture Sigma-Aldrich, Taufkirchen, Germany 
Macrophage SFM Cell culture Invitrogen, Carlsbad, USA 
M-CSF (E.coli expressed)  Cell culture R&D Systems, Minneapolis, USA 
Mikrobank Bacterial Storage 
system 
Storage of GBS Prolab Diagnostics, Richmond Hill, 
Canada 
Na2HPO4 (Disodium phosphate) PBS Merck, Darmstadt, Germany 
NaH2PO4 (Sodium Phosphate) PBS, PFA Merck, Darmstadt, Germany 
Na3C6H5O7.2H2O (Sodium 
citrate) 
ACD Merck, Darmstadt, Germany 
NaCl (Sodium chloride) PBS Merck, Darmstadt, Germany 
NaNO2 (Sodium nitrite) Measuring Nitrite Merck, Darmstadt, Germany 
NH4Cl (Ammonium chloride) ACK lysis Merck, Darmstadt, Germany 
Pancol human MACS Pan Biotech, Aidenbach, Germany 
Paraformaldehyde 36,5 – 38% PFA Sigma-Aldrich, Taufkirchen, Germany 
Percoll (density 1.131 g/ml) Miscellaneous GE Healthcare, Uppsala, Sweden 
RPMI 1640 L-Glutamine Miscellaneous Pan Biotech, Aidenbach, Germany 
RPMI 1640 GlutaMAX Cell culture Invitrogen, Carlsbad, USA 
Trypan blue (0,2% in 0,9% NaCl) Cell culture Sigma-Aldrich, Taufkirchen, Germany 
Xylol (>98 pure) Histology Merck, Darmstadt, Germany 
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Table 10: Expandable material 
Material Application Manufacturer 
   
4-well chamber slide Cytochemistry Nunc, Wiesbaden, Germany 
BD Discardit II 2 ml, 5 ml, 10 ml, 20 
ml (syringes) 
Miscellaneous BD Biosciences, Franklin Lakes, USA 
BD Falcon 40 μM Cell Strainer Miscellaneous BD Biosciences, Franklin Lakes, USA 
BD Microlance 3 20G, 22G, 27G 
(cannulas) 
Miscellaneous BD Biosciences, Franklin Lakes, USA 
BD Plastipak 1 ml (syringes) Miscellaneous BD Biosciences, Franklin Lakes, USA 
Biosphere Filter Tips 200 µl, 1000 µl Miscellaneous Sarstedt, Nümbrecht, Germany 
Bottle-Top-Filter 500 ml, 0,2 µm Miscellaneous Nalgene, Penfield, USA 
Cell culture plate (96 well) Miscellaneous Greiner, Kremsmünster, Austria 
Cell scraper 25 cm Cell culture Sarstedt, Nümbrecht, Germany 
Cord Blood System 150 ML CPD MACS Marco Pharma, Langen, Germany 
Cryo Tube Vials Cell culture Nunc, Wiesbaden, Germany 
Disposable latex gloves Miscellaneous Hartmann, Heidenheim, Germany 
Disposable nitrile gloves Miscellaneous Hartmann, Heidenheim, Germany 
Falcon Tubes (15 and 50 ml) Miscellaneous Sarstedt, Nümbrecht, Germany 
Glass Pasteur pipette Miscellaneous Brand, Wertheim, Germany 
Micro Pipettes 50 + 100 µl Blood samples Megro, Wesel, Germany 
Microtest 96 well (plate) ELISA  BD Biosciences, Franklin Lakes, USA 
Microtome Blades R35 Type 50 Histology Feather, Osaka, Japan 
MS Columns (Separation columns) MACS Miltenyi Biotech, Bergisch Gladbach, 
Germany 
Multiwell 24 well (plate) Cell culture BD Biosciences, Franklin Lakes, USA 
Multiwell 6 well (plate) Cell culture BD Biosciences, Franklin Lakes, USA 
Pipettes (2 ml, 5 ml, 10 ml, 25 ml)  Miscellaneous Sarstedt, Nümbrecht, Germany 
Reaction cups (1.5 and 2 ml)  Miscellaneous Sarstedt, Nümbrecht, Germany 
Rotilabo embedding cassettes Histology Carl Roth, Karlsruhe, Germany 
Safe Seal Tips 10 µl, 20 µl Miscellaneous Biozym, Hessisch Oldendorf, Germany 
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Material Application Manufacturer 
   
Shandon paper card Cytospin Thermo Scientific, Fremont, USA 
Superfrost Plus Microscope slides  Histology Menzel, Braunschweig, Germany 
Tips (10μl, 100μl and 1000μl) Miscellaneous Sarstedt, Nümbrecht, Germany 
Tube 5 ml (flow cytometry) Flow cytometry Sarstedt, Nümbrecht, Germany 
 
Table 11: Lab equipment 
Device Application Manufacturer 
   
Accu-jet pro Miscellaneous Brand, Wertheim, Germany 
Balance CP224S Miscellaneous Sartorius, Göttingen, Germany 
Balance PJ400 Miscellaneous Mettler-Toledo, Greifensee, Switzerland 
Centrifuge 5417R Miscellaneous Eppendorf, Hamburg, Germany 
Centrifuge 5810R Miscellaneous Eppendorf, Hamburg, Germany 
Cold plate EG1130 Histology Leica, Wetzlar, Germany 
Cryo 1°C Freezing Container Cell culture Nalgene, Penfield, USA 
EMax Endpoint ELISA Microplate 
Reader 
ELISA Molecular devices, Sunnyvale, USA 
Finnpipette 0.2 – 2 µl Miscellaneous Thermo Scientific, Fremont, USA 
Finnpipette 2 – 20 µl Miscellaneous Thermo Scientific, Fremont, USA 
Finnpipette 20 – 200 µl Miscellaneous Thermo Scientific, Fremont, USA 
Finnpipette 100 – 1000 µl Miscellaneous Thermo Scientific, Fremont, USA 
Freezer (-20°C)  Miscellaneous Liebherr, Kirchdorf an der Iller, Germany 
Freezer (-80°C) Forma 900 series Miscellaneous Thermo Scientific, Fremont, USA 
Hand counter T120 Miscellaneous Baumer IVO, Villingen-Schwenningen, 
Germany 
Implen Nano Photometer Bacteria Implen, Munich, Germany 
Incubator BBD 6220 Cell culture Heraeus, Hanau, Germany 
Incubator WTC Binder Miscellaneous Binder, Tuttlingen, Germany 
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Device Application Manufacturer 
   
Laminar flow KS 12 Miscellaneous Thermo Scientific, Fremont, USA 
Liquid nitrogen storage tank Miscellaneous German Cryo, Grevenbroich, Germany 
MACS Multi Stand MACS Miltenyi, Bergisch Gladbach, Germany 
Microscope (cell culture) Miscellaneous Carl Zeiss, Wetzlar, Germany 
Microtome RM 2145 Histology Leica, Wetzlar, Germany 
Neubauer chamber improved Miscellaneous HBG Precicolor, Giessen, Germany 
Rotilabo-Mini-Centrifuge Miscellaneous Carl Roth, Karlsruhe, Germany 
Shandon Cytoclip Cytospin Thermo Scientific, Fremont, USA 
Shandon Cytofunnel Cytospin Thermo Scientific, Fremont, USA 
Shandon Cytospin 4 
Cytocentrifuge 
Cytospin Thermo Scientific, Fremont, USA 
Signal timer Miscellaneous Carl Roth, Karlsruhe, Germany 
Ventana Nexes autostainer Histology Ventana, Tucson, USA 
Water bath HI1210 Histology Leica, Wetzlar, Germany 
Water bath TW20 Cell culture Julabo, Seelbach, Germany 
Zeiss Axio Imager M1 Histology Carl Zeiss, Wetzlar, Germany 
 
Table 12: Software 
Software Company  
  
Axio Vision 4.6 Zeiss, Wetzlar, Germany 
BD FACSDiva software BD Biosciences, Franklin Lakes, USA 
Graph Pad Prism 4.0 Graph Pad Software, La Jolla, USA 
Microsoft Office 2010 Microsoft Corporation, Redmond, USA 
SoftMax Pro Data Acquistion & Analysis 
Software 
Molecular devices, Sunnyvale, USA 
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3  RESULTS 
3.1 GENERATION AND CHARACTERIZATION OF 
HUMANIZED MICE 
 
After transplantation of human CD34+ hematopoietic stem cells into neonatal 
NOD.scid IL2Rnull (NSG) mice by intrahepatic injection (Fig. 1), the animals 
developed human CD45+ leukocytes in all analyzed organs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Cells positive for the human leukocyte marker CD45 were detected via flow 
cytometry in spleen, lung, liver, bone marrow (BM), mesenteric lymph nodes (mLN), 
peritoneum and peripheral blood (pb) (Fig. 2A). Human leukocytes constituted with 
an average of 41% viable cells in the lung, 50% in the pb, 59% in the BM, 64% in the 
spleen, 78% in the liver, and almost exclusively made up the mLN (91%). The 
peritoneum of naïve humanized NSG mice contained 7% of human CD45+ 
Fig. 1: Schematic of humanization of NSG mice with human CD34+ hematopoietic stem 
cells after conditioning (irradiation) and subsequent infection with GBS and treatment. 
Images: Biolegend; Environmental Health Services; Instituto de Bioquímica Clínica; 
Jackson Laboratories; Royal Society for the Prevention of Cruelty to Animals; Wikipedia. 
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leukocytes. The development of a complete human immune system was further 
monitored by the analysis of various immune cell subtypes. Staining of CD3 revealed 
considerable numbers of T cells in mLN (50% of live cells), liver (39%) and lung 
(30%). The pb (21%) and spleen (18%) had lower amounts, while peritoneum (6%) 
and BM (5%) contained low numbers of T cells (Fig. 2B). Whereas the proportion of 
T cells displayed higher variances, B cell numbers were more consistent, and varied 
between 39% of live cells in the spleen and 11% in the lung. The only exception was 
the peritoneum with 3% (Fig. 2C). Upon humanization, not only leukocytes of 
lymphoid linage, but also CD33+ myeloid cells were present. Considerable numbers 
were detected in the bone marrow (18% of CD45+ cells), lung (14%) and liver (12%), 
while pB (7%), peritoneum (4%) and spleen (3%) showed low amounts (Fig. 2D). 
Humanized mice only generated few CD66 expressing granulocytes. In most organs 
the proportion was less than 0.06% of CD45+ cells, with the exception of the liver 
(0.5%) and even more so the BM (4.3%) (Fig. 2E). However, not only major subsets 
of human immune cells developed in the humanized mice. Examination of the human 
T cells revealed the presence of CD3+ CD4+ helper T cells (Fig. 2F) and CD3+ CD8+ 
cytotoxic T cells (Fig. 2G) indicating normal T cell development.  
Histological analysis was performed to confirm the results from flow cytometry. 
Sections from spleen, mLN, liver, lung, kidney and brain were stained for human 
leukocytes (CD45), T cells (CD3), B cells (CD79a) and macrophages (CD68). 
Consistent with flow cytometric results, mLN and spleen contained very high 
numbers of human CD45+ cells. Lung and especially the liver showed markedly 
reduced leukocyte counts. This was caused by the fact that prior to flow cytometric 
staining, the immune cells from lung and liver were enriched by density gradient 
centrifugation in Percoll. Considerable low numbers of human leukocytes were also 
present in the kidney. Humanized mice without infection showed no human CD45+ 
leukocytes in the brain. Staining for T and B cells showed similar results. Human 
CD68+ macrophages could be detected in most organs except the brain (Fig. 3). 
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Fig. 2: Flow cytometric analysis of the 
percentage of CD45+ leukocytes (A), 
CD3+ T cells (B), CD19+ B cells (C), 
CD33+ myeloid cells (D) and CD66+ 
granulocytes (E) in pb, spleen, liver, 
lung, BM, mLN and peritoneum. Number 
of animals tested (n). Each symbol 
represents one mouse; the horizontal 
line denotes the mean, the error bars 
the standard error of the mean. 
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Fig. 3: Immunohistochemical staining for CD45+ leukocytes, CD3+ T cells, CD79a+ B 
cells and CD68+ macrophages in spleen, kidney, liver, lung, brain, mLN of naive 
humanized mice. Animals were infected with moderate doses of GBS (106) and 
analyzed at day 3. Scale bar = 100 µm; objective used 40x.  
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To monitor the development of the human immune system in the animals, blood was 
drawn starting 6-8 weeks post transplantation. While the human immune system with 
all immune cell subsets is already present at this point in time, the composition is still 
subject to change. A good example is the levels of T and B cells in the pb (Fig 4). 
Between 6 and 10 weeks after injection of CD34+ hematopoietic stem cells, CD19+ B 
cell percentages remained relatively constant at a high level, while CD3+ T cell 
proportions rose very slowly. After 10 weeks, B cell percentages began to decline 
and T cell proportions increased more distinctively, until 30 weeks of age. Here the 
proportions of B and T cells were equal.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Flow cytometric analysis of the percentage of CD19+ B cells and CD3+ T cells in 
pb of humanized mice between 6 and 30 weeks post transplantation of CD34+ 
hematopoietic stem cells. Number of animals tested at each time point (n). Values in 
table are percentage of B or T cells of live cells (top) with standard error of the mean 
(bottom). 
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Humanized mice have low proportions of myeloid cells (Fig. 2), mostly due to the 
lack of human specific growth factors for the myeloid linage (M-CSF, GM-CSF). 
Hence, the capacity of myeloid progenitors and monocytes to differentiate into 
functional macrophages was analyzed. Single cell suspensions from bone marrow of 
humanized mice were differentiated in vitro for 7 days to obtain macrophages. After 7 
days, the cells were stimulated 24 h with 1 µM CpG and 100 ng/ml LPS. While only 
33% of unstimulated cells expressed the maturation and activation marker CD86, 
stimulation induced the expression of CD86 in 81% of live CD33+ cells (Fig. 5). This 
indicates that the differentiation of macrophages from humanized mice, as well as 
their functional maturation and activation is possible, given the presence of the 
appropriate growth factors and stimuli.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5: In vitro differentiation and stimulation of BMDM. Diff-Quick staining of cells 
after in vitro differentiation (A). Scale bar = 100 µm; objective used 40x. Flow 
cytometric analysis of CD45+ CD33+ myeloid cells after differentiation (B) and 
maturation and activation marker (CD86) expression of unstimulated and stimulated 
cells (C). 
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3.2 INFECTION MODEL 
 
3.2.1 CHARACTERIZATION OF GBS INFECTION IN HUMANIZED MICE 
 
For infection of the humanized mice, GBS was grown on sheep blood agar plates 
and suspended in PBS. To be able to infect the animals with a standardized dose of 
bacteria, the correct amount of live GBS at a certain optical density (OD) had to be 
determined. A total of 12 independent experiments revealed that a solution at OD 
0.400 contained 2x108 live GBS (Fig. 6). In order to exclude possible complications 
with culturing, generation of bacterial suspension and adjustment of OD, and 
therefore incorrect doses, dilutions of the GBS suspension were plated and cultivated 
for each infection experiment.  
 
 
 
 
 
 
 
 
Humanized mice were a completely new animal model for GBS infections. Hence, a 
suitable infectious dose had to be determined. Animals were therefore injected intra 
peritoneally with various doses of bacteria and the survival was monitored. Infection 
with 5x108 bacteria led to the death of all animals within 2 days. The doses 5x107 
and 107 resulted in the death of 75% of the animals at day 1 and day 2 respectively. 
Reduction of the number of injected pathogens drastically increased the rate of 
survival. While 106 GBS induced the death of 20% of mice, 5x105 and lower doses 
lead to the death of less than 10% of infected animals (Fig. 7). For the analysis of the 
effects of an acute high dose infection, the dose of 107 GBS was chosen. Here 
animals could be challenged with a relatively high dose of live bacteria, but if they 
were killed 24 h after infection, 75% of live mice were available for analysis. In order 
Fig. 6: Number of CFU of a GBS suspension in PBS adjusted to the OD of 0.400. Each 
symbol represents one experiment (n=12); the horizontal line denotes the mean, the 
error bars the standard error of the mean. 
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to be able to determine the effects of moderate to long term GBS infection on the 
immune system of humanized mice, the dose of 106 GBS was chosen. This dose 
represented a moderate amount of live bacteria, which still enabled the analysis of 
80% of live mice 3d and 7d after infection.  
0 1 2 3 4 5 6 7 8 9
0
20
40
60
80
100
1x10
5
 (n=11)
5x10
5
 (n=2)
1x10
6
 (n=20)
1x10
7
 (n=4)
5x10
7
 (n=4)
5x10
8
 (n=4)
days
%
 s
u
rv
iv
a
l
 
 
 
Although humanized NSG mice lack mature murine B, T and NK cells, they still 
feature murine cells of the myeloid linage. Especially granulocytes and macrophages 
are involved in fighting off bacterial infections. In order to ensure that the human 
immune system was the key player in coping with the GBS infection, neonatal NSG 
littermates were radiated with 1 Gy. Subsequently, half of the mice were transplanted 
with human CD34+ hematopoietic stem cells. After approximately 3 months, when the 
human immune system in the humanized mice was fully developed, both groups 
(humanized and radiated only) were infected with 106 GBS and their survival was 
monitored. After 2 days, more than 90% (10/11) of the radiated only mice died, 
whereas 100% (11/11) of the humanized animals survived (Fig. 8). This indicated 
that the human immune system in the humanized mice plays a major role in fighting 
off the bacterial infection.  
Fig. 7: Survival in days of humanized mice infected with various doses of GBS from 
1x105 to 5x108. Number of animals in each group (n).  
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After determining suitable infectious doses and confirming the crucial role of the 
human immune system, humanized mice were infected with GBS and various 
parameters were analyzed.  
 
3.2.2 DISEASE PROGRESSION IN GBS INFECTED HUMANIZED MICE 
 
In order to analyze systemic distribution and clearance of live bacteria, various 
organs (spleen, kidney, liver, lung, brain, BM and peritoneum) were analyzed for 
colony forming units (CFU) (Table 13). After injection of GBS (either 106 or 107 CFU) 
intraperitoneally (ip), the bacteria rapidly spread systemically. After 24 h of high dose 
infection, none of the infected animals (n=10) was able to completely clear the 
pathogen from their system (supplement table 1). The peritoneum, as the site of 
initial infection harbored the highest amount of bacteria. At this time point, high CFU 
counts could also be found in the spleen, kidney, liver and lung. Lower numbers of 
live bacteria also spread into the BM and 6/10 animals showed low amounts of GBS 
in the brain. Three days after moderate dose infection, 4/10 mice managed to clear 
the GBS infection entirely. The remaining 6 animals featured the highest 
concentration of CFU in the liver, followed by the kidney. Low amounts of GBS were 
also found in BM, spleen and lung. Peritoneal cavities contained only minimal 
amounts of live bacteria. None of the infected animals displayed GBS in the brain. 
Fig. 8: Survival in days of humanized (blue) and radiated only (red) mice infected with 
106 GBS. Number of animals in each group (n=11). Statistical analysis: Log-rank 
(Mantel-Cox) test (***=p<0.0001) 
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Seven days post infection, more animals (4/6) were able to completely clear live GBS 
systemically. The remaining mice showed high amounts of GBS in the kidney. Low 
numbers of CFU were found in the peritoneum, the lung and even lower CFU counts 
were detected in BM and liver. Spleen and brain were entirely devoid of live bacteria 
after 7 days of infection. 
Table 13: CFU per g of tissue (except in BM and peritoneal cavity where CFU were 
calculated per ml) in various organs of humanized mice infected with GBS.   
 1d 107 GBS 3d 106 GBS 7d 106 GBS 
spleen 
Mean 
SEM 
n 
8,71x10
7
 
4,25x10
7
 
10 
Mean 
SEM 
n 
5,00x10
2
 
5,00x10
2
 
10 
Mean 
SEM 
n 
0 
0 
6 
kidney 
Mean 
SEM 
n 
2,38x10
7
 
1,15x10
7
 
10 
Mean 
SEM 
n 
6,00x10
3
 
6,00x10
3
 
10 
Mean 
SEM 
n 
4,19x10
6
 
4,19x10
6
 
6 
liver 
Mean 
SEM 
n 
2,92x10
7
 
1,26x10
7
 
10 
Mean 
SEM 
n 
2,69x10
4
 
2,65x10
4
 
10 
Mean 
SEM 
n 
1,27x10
1
 
1,27x10
1
 
6 
lung 
Mean 
SEM 
n 
4,03x10
7
 
1,50x10
7
 
10 
Mean 
SEM 
n 
1,18x10
2
 
1,18x10
2
 
10 
Mean 
SEM 
n 
2,22x10
2
 
2,22x10
2
 
6 
brain 
Mean 
SEM 
n 
1,35x10
5
 
5,54x10
4
 
10 
Mean 
SEM 
n 
0 
0 
10 
Mean 
SEM 
n 
0 
0 
6 
bone marrow 
Mean 
SEM 
n 
7,14x10
5
 
4,12x10
5
 
10 
Mean 
SEM 
n 
7,40x10
2
 
6,18x10
2
 
10 
Mean 
SEM 
n 
3,33x10
1
 
3,33x10
1
 
6 
peritoneal cavity 
Mean 
SEM 
n 
3,62x10
8
 
2,21x10
8
 
10 
Mean 
SEM 
n 
1,00x10
1
 
1,00x10
1
 
10 
Mean 
SEM 
n 
7,20x10
2
 
7,20x10
2
 
6 
 
3.2.3 CHARACTERIZATION OF ORGAN DAMAGE AFTER GBS INFECTION 
 
GBS sepsis generally leads to organ damage, especially in the lung and the brain of 
human neonates. Therefore spleen, kidney, liver, lung and brain in infected 
humanized mice were screened for histopathological changes. No changes were 
found in animals infected with moderate doses of GBS and also for high dose 
infected animals after 1 day (supplement Fig. 1-4; data not shown). However, high 
dose infected animals, which were moribund at day 2 showed leukocyte infiltration in 
the lung (Fig. 9A,B) and hemosiderin deposits in the spleen (Fig. 9C)  
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3.2.4 EFFECT OF INFECTION ON CELL COUNT 
 
For determining the general effect of GBS infection on cell proliferation and/or 
migration, the total cell count of different organs was determined. While infection with 
a high dose (107) of GBS induced a slight increase in splenocytes and a reduced cell 
count in the BM, these changes were not statistically significant (Fig. 10A). Infection 
with a moderate dose (106) of GBS induced an increase in total cell count in spleen 
and liver 3 days post infection, although not significant both times. However, the 
decrease in the amount of cells in the BM was significant (Fig. 10B). This effect was 
most likely caused by migration of leukocytes from the bone marrow into the 
periphery. Seven days after infection with a moderate dose of GBS, the increase in 
splenocytes was significant (Fig. 10C). This was probably caused by proliferation of 
lymphocytes in the spleen. The total cell count in the BM also increased compared to 
3 days post infection, and began to align with the level of uninfected animals. This 
was most likely caused by proliferation of stem and progenitor cells. 
Fig. 9: Hematoxylin & Eosin staining of 
lung (A,B) and spleen. Animals were 
infected with high doses of GBS (107) 
and analyzed at day 2. Scale bar = 100 
µm; objective used 20x (A) and 40x 
(B,C). Arrows indicate leukocyte 
infiltration (A,B) and hemosiderin 
deposits (C).  
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Fig. 10: Total cell count of spleen, liver, lung, BM and peritoneum of humanized mice. 
After 1 day of high dose infection (107 GBS) (A), 3 days of moderate dose infection (106 
GBS) (B) and 7 days of moderate dose infection (106 GBS) (C). Number of animals per 
group (n). Error bars denote the standard error of the mean. Statistical analysis: Two-
way ANOVA (*=p<0.05; **=p<0.01) with Bonferroni posttest (*=p<0.05; **=p<0.01). 
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3.2.5 RESPONSE OF THE HUMAN IMMUNE SYSTEM – MIGRATION AND 
PROLIFERATION 
 
Aside from the changes in total cell count per organ, flow cytometric analysis was 
conducted to analyze the changes in immune cell populations. Although none of the 
changes in CD45+ leukocytes were statistically significant, they coincided well with 
the changes in total cell counts (Fig. 11A). Infection led to a general increase in the 
number of human leukocytes in the spleen and the peritoneum. Moderate dose 
infection for 3 and 7 days decreased the number of CD45+ cells in the BM but 
increased it in the liver (Fig. 11A). The number of CD3+ T cells generally increased 
upon infection in the peritoneum and was probably the reason for the increased 
number of leukocytes there. Moderate dose infection also increased the T cell count 
in the liver after 7 days (Fig. 11B). The analysis of the two T cell subsets CD3+ CD4+ 
helper T cells and CD3+ CD8+ cytotoxic T cells revealed that the increase in T cells in 
the liver 7 days after moderate dose infection was mostly due to a rising helper T cell 
count and only a minor increase in cytotoxic T cells (Fig. 12). Changes in the T cell 
population were not statistically significant. High dose infection significantly increased 
the CD19+ B cell count in the spleen and the BM. Moderate dose infection led to 
significantly elevated numbers of B cells in the spleen after 3 days and to a not 
statistically significant rise in the liver after 7 days (Fig. 11C). Increase of T and B 
cells most likely caused the increment of leukocytes in the liver after 7 days of 
moderate dose infection. The number of CD33+ myeloid cells in the BM generally 
decreased after infection. This effect was accompanied by an increase in myeloid 
cells in the spleen as well as in the liver (Fig. 11D). Alterations in the myeloid cell 
population were not significant, however, they were present in all groups. GBS 
infection induced an increase in CD66+ granulocytes in the BM which was significant 
after 3 days of moderate dose infection. Moderate dose infection for 7 days and high 
dose infection also resulted in the increment of granulocytes in the liver and spleen, 
but only by tendency (Fig. 11E).  
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The human immune system that humanized mice develop is quite heterogenic. This 
can be seen in the high diversity of CD45+ cells in the pb (Fig. 2A). Therefore, a 
direct comparison of the same animals before and after infection by analyzing their 
blood was conducted. Flow cytometric analysis showed no marked changes in the 
percentage of human leucocytes after 24 h of high dose and 7 days of moderate 
dose infection. However, a significant decrease in CD45+ cells was determined 3 
days after moderate dose infection (Fig. 13A). CD3+ T cells were significantly 
elevated after 1 day (107 GBS) but remained unchanged after 3 days (106 GBS) (Fig. 
Fig. 11: Flow cytometric analysis of the total amount of CD45+ leukocytes (A), CD3+ T 
cells (B), CD19+ B cells (C), CD33+ myeloid cells (D) and CD66+ granulocytes (E) in 
spleen, liver, lung, BM and peritoneum. Animals were either not infected naïve mice 
(control), infected for 1 day with 107 GBS (INF 10E7 1d), infected for 3 days (INF 10E6 
3d) or 7 days (INF 10E6 7d) with 106 GBS. Number of animals in each group (n). 
Statistical analysis: Two-way ANOVA with Bonferroni posttest (*=p<0.05; **=p<0.01; 
***=p<0.001). ND means not determined. 
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13B). One day of infection with 107 GBS reduced the numbers of CD19+ B cells in 
the pb significantly. Moderate dose infection with GBS showed the same picture after 
3 days (Fig. 13C). Infection induced a significant increment in CD33+ myeloid cell 
levels in all groups. However, the increase was most pronounced after high dose 
infection for 24 h (Fig. 13D). Moderate doses of GBS lead to a slight reduction of 
CD66+ granulocytes after 3 days, but to an increase after 7d. High dose infection 
triggered a rise in granulocytes after 24 h (Fig. 13E).  
A 
B 
Fig. 12: Flow cytometric analysis of the total amount of CD3+ CD4+ helper T cells (A) 
and CD3+ CD8+ cytotoxic T cells (B) in spleen, liver, lung, BM and peritoneum. Animals 
were either not infected naïve mice (control), infected for 1 day with 107 GBS (INF 10E7 
1d), infected for 3 days (INF 10E6 3d) or 7 days (INF 10E6 7d) with 106 GBS. Number 
of animals in each group (n). Statistical analysis: Two-way ANOVA with Bonferroni 
posttest (no significance). ND means not determined. 
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Fig. 13: Flow cytometric analysis of CD45+ leukocytes (A), CD3+ T cells (B), CD19+ B 
cells (C), CD33+ myeloid cells (D) and CD66+ granulocytes (E) in the pb before (pre 
INF) and after (post INF) infection. Animals were either infected for 1 day with 107 GBS 
(1 day 107), infected for 3 days (3 days 106) or 7 days (7 days 106) with 106 GBS. 
Number of animals in each group: n=3-5 (1 day 107), n=6 (3 days 106) and n=5 (7 days 
106). Statistical analysis: Student’s paired t test (*=p<0.05; **=p<0.01). 
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The peritoneal cavity did not only represent the primary site of infection. Due to the 
low number of CD45+ cells in naïve mice, this organ proved to be well suited to 
monitor the influx of human leukocytes and immune cell subsets during infection (Fig. 
14). While high dose infection (107 GBS) induced increased levels of CD45+ cells 
after 1d, moderate GBS doses led to significantly elevated amounts of human 
leukocytes in the peritoneum after 3 and also 7 days (Fig. 14A). Flow cytometry was 
used to further analyze the types of immune cells, which migrated into the 
peritoneum upon infection. After 1d, mostly myeloid cells and granulocytes were 
responsible for the elevated leukocyte levels. Three days post infection, migrated T 
cells and also myeloid cells comprised the majority of PEC. At 7 days of infection, T 
cells represented the major human immune cell population, followed by B cells, 
which constituted a minor population prior to that time point (Fig. 14B). Of note is the 
significant growth of the CD66+ granulocyte population in the peritoneum after high 
dose infection, which was absent in moderate dose infection (Fig. 14C), whereas the 
increase in the amount of granulocytes in the BM was more pronounced in the 3 or 7 
days of moderate dose infection compared to the relatively short time span (1 day) of 
high dose infection (Fig. 14D). 
 
3.2.6 RESPONSE OF THE HUMAN IMMUNE SYSTEM – CYTOKINE 
PRODUCTION 
 
After showing that the human immune cells in the animals responded to the infection 
by migration and proliferation, the production of human specific cytokines, which 
trigger those reactions, was analyzed. High doses of GBS induced the release of 
substantial amounts of the pro-inflammatory cytokines TNF, IFNγ, IL-1β and IL-6. 
Also the chemokine IL-8, which acts as a chemoattractant for neutrophils, was 
significantly elevated after 24 h. But not only the production and release of pro-
inflammatory cytokines and chemokines were induced, also the anti-inflammatory 
cytokine IL-10, needed for counter-regulation of the inflammatory response, was 
released (Fig. 15A). Infection with moderate doses of GBS also triggered the release 
of cytokines and chemokines. On day 2 and day 3 post infection, TNF, IFNγ, IL-6 and 
IL-8 levels were slightly elevated. However, the changes were not significant and the 
cytokine and chemokine levels were rather low (except IL-8). IL-10 and especially IL-
1β remained practically unchanged (Fig. 15B).  
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Fig. 14: Flow cytometric analysis of CD45+ leukocytes (A), and CD3+ T cells, CD19+ B 
cells, CD33+ myeloid cells and CD66+ granulocytes (B) in PEC after infection. Flow 
cytometric analysis of the relative changes in CD66+ granulocytes in the PEC 
population (C) and BM cell population (D). Animals were either not infected (control), 
infected for 1 day with 107 GBS (INF 10E7 1d), infected for 3 days (INF 10E6 3d) or 7 
days (INF 10E6 7d) with 106 GBS. Number of animals in each group (n). Each symbol 
represents one mouse; the horizontal line denotes the mean, the error bars the 
standard error of the mean. Statistical analysis: One-way ANOVA (A**= p<0.01, A***= 
p<0.001) with Tukey posttest (*=p<0.05; **=p<0.01; ***=p<0.001). 
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Fig. 15: Multiplex analysis of the concentration (pg/ml) of TNF, IFNγ, IL-1β, IL-6, IL-8 
and IL-10 in serum of uninfected (day 0) and infected (day 1, 2, 3) animals. Mice were 
either infected with 107 GBS and tested after 1 day (A) or infected with 106 GBS and 
analyzed at day 2 and 3 (B). Number of animals per group: (A) day 0 (n=8), day 1 
(n=11); (B) day 0 (n=8), day 2 (n=12), day 3 (n=13). The error bars denote the standard 
error of the mean. Statistical analysis: (A) Student’s unpaired t test (*=p<0.05; 
**=p<0.01; ***=p<0.001); (B) One-way ANOVA (no significant differences). 
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3.3 EFFECT OF TREATMENT ON DISEASE PROGRESSION 
 
3.3.1 TREATMENT REGIMEN 
 
After establishing and analyzing the new animal model for GBS infection using 
humanized mice, the effect of treatment on disease progression (clearance of live 
bacteria, survival rate, organ damage) and effect on human immune system 
(migration and proliferation of leukocytes, cytokine production, clearance of GBS) 
was analyzed. The glucocorticoid Betamethasone is a drug routinely used for lung 
maturation in the clinic. The treatment regimen for human neonates is 2x 5 mg/kg 
given to the mother, 24 h apart. In the moderate dose GBS infection model (106 CFU 
for 3 or 7 days) the same regimen was used 24 h post infection (Fig. 16A). In the 
high dose infection model (107 GBS for 1 day) Betamethasone (5 mg/kg) was only 
given once, 3 h after infection due to the long biological half-life of 36-54 h (Tegethoff 
et al. 2009) (Fig. 16B). The non-steroidal anti-inflammatory drug Indomethacin is 
used for tocolysis. Since the LD50 of Indomethacin for mice is very low (11.8 mg/kg) 
(Material safety data sheet) and the treatment regimen for humans varies (Van Der 
Poole 1998), 3 mg/kg Indomethacin were given using the same regimen as 
Betamethasone.  
 
Fig. 16: Schematic of the infection and the subsequent treatment regimen for the 
moderate dose (A) and high dose (B) infection model. 
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3.3.2 IMPACT OF TREATMENT ON CLEARANCE OF BACTERIA 
 
The clearance of live bacteria by immune cells is crucial for fighting off infections. 
Drugs which adversely affect the killing of pathogens usually exacerbate bacterial 
infections. Betamethasone treatment led to a significant reduction of the systemic 
CFU count (all analyzed organs combined) in the high dose infection model (107 
GBS). It further led to an increased clearance in the peritoneum (significant), lung 
and spleen (Fig. 17A). The moderate dose infection model (106 GBS) displayed 
increased amounts of live bacteria with both drugs, 3 as well as 7 days after 
infection. At day 3, Betamethasone was responsible for a significantly higher 
systemic CFU count (all organs combined). Increased amounts of live bacteria were 
found in every organ except the peritoneum (Fig. 17B). While Indomethacin did not 
induce significantly higher CFU counts, treatment did result in increased amounts of 
live bacteria in kidney, lung and BM (Fig. 17C) 3 days post infection. Betamethasone 
treatment did not seem to have an effect on bacterial clearance 7 days after 
moderate dose infection (Fig. 17D). The effect of Indomethacin, 7 days post infection 
seemed to be a reduction in bacterial clearance (Fig. 17E).  
GBS feature mechanisms to cross the blood brain barrier, and are known to cause 
meningitis. Therefore the presence of live bacteria in the brain, and the effect of 
treatment, was of special importance in our animal model. In the high dose infection 
model, 24 h post infection, 4/7 vehicle-treated animals and 4/8 Betamethasone-
treated mice had live bacteria in the brain (Fig. 18A). Therefore treatment did not 
markedly affect the spreading of live GBS into the brain. In the moderate dose 
infection model however, CFU were detected only in animals which either received 
Betamethasone or Indomethacin. After 3 days, live bacteria were detected in 0/10 
animals receiving PBS, in contrast to 3/10 receiving Betamethasone and 2/10 
receiving Indomethacin (Fig. 18B). Seven days post infection, 1/2 mice in the 
Indomethacin treatment group had CFU in the brain. Animals in the PBS (n=6) and 
Betamethasone (n=3) treatment group were clean (Fig. 18C). 
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Fig. 17: CFU count in spleen, kidney, liver, lung, brain, BM and peritoneum of infected 
and vehicle-treated (PBS) or infected and Betamethasone (BETA)- or Indomethacin 
(INDO)-treated mice. CFU count was calculated per g of tissue except for BM and 
peritoneal cavity where it was calculated per ml of cell suspension. Animals were either 
infected with 107 GBS and analyzed after 1 day (A) or infected with 106 GBS and 
analyzed at day 3 (B;C) or day 7 (D;E). Number of animals per group (n). The error 
bars denote the standard error of the mean. Statistical analysis: Two-way ANOVA (A*= 
p<0.05) with Bonferroni posttest (*=p<0.05). 
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3.3.3 EFFECT OF TREATMENT ON TOTAL CELL COUNT 
 
Betamethasone treatment did not affect the total cell count in high dose infected 
animals, 24 h after infection, except a slight decrease in PEC (Fig. 19A). In contrast, 
total cell count in the moderate dose infection model was affected by the treatment. 
Both drugs reduced the number of splenocytes significantly 3 days after infection 
(Fig. 19B). Furthermore, both drugs slightly decreased the leukocyte count in the 
liver. Treatment had no marked effect at day 7 in the moderate dose infection model 
(Fig. 19C). 
A 
C 
B 
Fig. 18: CFU count per g of brain tissue in 
infected and vehicle-treated (PBS) or 
infected and Betamethasone (BETA)- or 
Indomethacin (INDO)-treated mice. 
Animals were either infected with 107 GBS 
and tested after 1 day (A) or infected with 
106 GBS and analyzed at day 3 (B) or day 
7 (C). Number of animals per group (n). 
Each symbol represents one mouse; the 
horizontal line denotes the mean, the error 
bars the standard error of the mean. 
Statistical analysis: One-way ANOVA with 
Tukey posttest (no significant differences 
detected). 
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Fig. 19: Total cell count of spleen, liver, lung, BM and peritoneum of infected and 
vehicle (PBS)-, Betamethasone (BETA)- or Indomethacin (INDO)-treated humanized 
mice. After 1 day of 107 GBS (A), 3 days of 106 GBS (B) or 7 days of 106 GBS (C). 
Number of animals per group (n). The error bars denote the standard error of the mean. 
Statistical analysis: Two-way ANOVA with Bonferroni posttest (*=p<0.05; **=p<0.01). 
A 
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3.3.4 EFFECT OF TREATMENT ON MIGRATION AND PROLIFERATION OF 
LEUKOCYTES 
 
Flow cytometric analysis was used to determine if treatment affected the total 
amount of leukocytes and leukocyte subsets. This was done to analyze the effect of 
Betamethasone and Indomethacin on immune cell migration and proliferation during 
GBS infection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20: Flow cytometric analysis of CD45+ leukocytes (A), CD3+ T cells (B), CD19+ B 
cells (C), CD33+ myeloid cells (D) and CD66+ granulocytes (E) in spleen, liver, lung, BM 
and peritoneum. Animals were high dose (107 GBS) infected, treated with either vehicle 
(PBS) or Betamethasone (BETA) and analyzed after 1 day. Number of animals per 
group (n). The error bars denote the standard error of the mean. Statistical analysis: 
Two-way ANOVA with Bonferroni posttest (no significant differences detected). 
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In the high dose infection model (107 GBS, 24 h), Betamethasone treatment had no 
effect on total CD45+ leukocyte count in all organs (spleen, liver, lung, BM) except 
the peritoneal cavity, where it led to increased amounts of leukocytes (not significant) 
(Fig. 20A). Unaffected by treatment were also CD3+ T cell (Fig. 20B), B cell (Fig. 
20C) and CD33+ myeloid cell count (Fig. 20D). However, Betamethasone led to an 
increased amount of CD66+ granulocytes in peritoneum and liver (not significant) and 
to the complete absence of this cell type in the spleen (Fig. 20E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21: Flow cytometric analysis of CD45+ leukocytes (A), CD3+ T cells (B), CD19+ B 
cells (C), CD33+ myeloid cells (D) and CD66+ granulocytes (E) in spleen, liver, lung, BM 
and peritoneum. Animals were infected with moderate doses of GBS (106), treated with 
(PBS), Betamethasone (BETA) or Indomethacin (INDO) and analyzed after 3 days. 
Number of animals per group (n). The error bars denote the standard error of the mean. 
Statistical analysis: Two-way ANOVA with Bonferroni posttest (*=p<0.05; **=p<0.01). 
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In the moderate dose infection model (106 GBS) both drugs induced changes in 
leukocyte populations after 3 days. Both Betamethasone and Indomethacin led to a 
significant reduction in CD45+ cell count in the spleen (Fig. 21A), which was 
explained by reduced amounts of T, B and myeloid cells. Furthermore, the two 
different treatments led to a significantly lower CD3+ T cell count in the spleen, and 
also a slightly lower amount of T cells in the BM (Fig. 21B). Both drugs also induced 
a significant decrease in CD19+ cells in the spleen and Betamethasone caused a 
significantly increased B cell count in the BM. Indomethacin had the same effect, but 
not significantly (Fig. 21C). CD33+ myeloid cell counts in the spleen were lowered by 
both drugs, but only by tendency. Treatment also resulted in a reduction of myeloid 
cells in the BM, for Betamethasone this effect was significant (Fig. 21D). 
Betamethasone induced granulocytes in 1/9 of treated animals in peritoneum and 
spleen, which were completely absent in the other treatment groups (Fig. 21E). 
After 7 days treatment did not induce significant changes. However, Betamethasone 
led to an increase in CD45+ cells in the peritoneum in the moderate dose infection 
model (Fig. 22A), which was explained by an increase in T cell numbers (Fig. 22B). B 
cell (Fig. 22C), myeloid cell (Fig. 22D) and granulocyte populations (Fig. 22E) and 
were relatively unaffected by treatment.  
Neither Betamethasone nor Indomethacin treatment had major effects on T cell 
subsets (Fig. 23). The pronounced increase in CD3+ CD8+ cytotoxic T cells in the 
spleen should not be considered important since it was the value of only one animal. 
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Fig. 22: Flow cytometric analysis of CD45+ leukocytes (A), CD3+ T cells (B), CD19+ B 
cells (C), CD33+ myeloid cells (D) and CD66+ granulocytes (E) in spleen, liver, lung, BM 
and peritoneum. Animals were infected with moderate doses of GBS (106) and treated 
either with vehicle (PBS), Betamethasone (BETA) or Indomethacin (INDO) and 
analyzed after 7 days. Number of animals per group (n). Exception: spleen INF 10E6 
7d (CD19 and CD3) n=1. The error bars denote the standard error of the mean. 
Statistical analysis: Two-way ANOVA with Bonferroni posttest (no significant 
differences). ND means not determined. 
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Due to the fact that pb can be drawn and analyzed before and after infection and 
treatment, this procedure enabled a direct comparison of immune cell populations in 
the same animal. Therefore, the heterogeneity of the human immune system in 
humanized mice had a lower impact, and slighter changes in cell populations, 
caused by treatment, were detectable.  
Fig. 23: Flow cytometric analysis of the total amount of CD3+ CD4+ helper T cells 
(A,C,E) and CD3+ CD8+ cytotoxic T cells (B,D,F) in spleen, liver, lung, BM and 
peritoneum. Animals were infected with 107 GBS for 1 day (A,B), 106 GBS for 3 (C,D) 
or 7 days (E,F). The infected mice were either vehicle- (PBS), Betamethasone (BETA)- 
or Indomethacin (INDO)-treated and analyzed. Number of animals per group (n). 
Exception: spleen INF 10E6 7d (BETA) n=1. The error bars denote the standard error 
of the mean. Statistical analysis: Two-way ANOVA with Bonferroni posttest (no 
significant differences). ND means not determined. 
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Fig. 24: Flow cytometric analysis of CD45+ leukocytes (A), CD3+ T cells (B), CD19+ B 
cells (C), CD33+ myeloid cells (D) and CD66+ granulocytes (E) in the pb before (pre 
INF) and after (post INF) infection. Animals were infected for 1 day with 107 GBS and 
received either vehicle (PBS) or Betamethasone once 3 h post infection. Number of 
animals per group: n=3-5 (PBS), n=2-5 (Betamethasone). Each symbol represents one 
mouse; the horizontal line denotes the mean, the error bars the standard error of the 
mean. Statistical analysis: Student‘s paired t test (*=p<0.05; **=p<0.01). 
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Fig. 25: Flow cytometric analysis of CD45+ leukocytes (A), CD3+ T cells (B), CD19+ B 
cells (C), CD33+ myeloid cells (D) and CD66+ granulocytes (E) in the pb before (pre 
INF) and after (post INF) infection. Animals were infected for 3 days with 106 GBS and 
received either vehicle (PBS), Betamethasone or Indomethacin twice (24 h and 48 h) 
post infection. Number of animals in each group: n=6 (PBS), n=7 (Betamethasone), 
n=6-7 (Indomethacin). Each symbol represents one mouse; the horizontal line denotes 
the mean, the error bars the standard error of the mean. Statistical analysis: Student’s 
paired t test (*=p<0.05; **=p<0.01; ***=p<0.001). 
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High dose infection (107 GBS) for 1 day had no major impact on CD45+ leukocytes in 
the pb, neither with nor without treatment. CD3+ T cells were elevated in both groups, 
however in untreated animals (PBS) this effect was significant. Infection led to a 
significant decrease in CD19+ B cells, which was absent after Betamethasone 
administration. Treatment did not affect the significant rise in myeloid CD33+ cells in 
the pb after high dose infection. Also, the slight rise in percentage of granulocytes 
was practically absent with Betamethasone treatment (Fig. 24). 
Fig. 26: Flow cytometric analysis of CD45+ leukocytes (A), CD33+ myeloid cells (B) and 
CD66+ granulocytes (C) in the pb before (pre INF) and after (post INF) infection. 
Animals were infected for 7 days with 106 GBS and received either vehicle (PBS), 
Betamethasone or Indomethacin twice (24 h and 48 h) post infection. Number of 
animals in each group: n=5-6 (PBS), n=3 (Betamethasone), n=2 (Indomethacin). Each 
symbol represents one mouse; the horizontal line denotes the mean, the error bars the 
standard error of the mean. Statistical analysis: Student’s paired t test (no significant 
differences). 
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In the moderate dose infection model (106 GBS) the amount of CD45+ leukocytes in 
the pb decreased with Betamethasone and Indomethacin and also without treatment. 
However, a significant reduction was only observed in vehicle treated animals 3 days 
post infection. The size of the T cell population was unaffected while CD19+ B cells 
significantly decreased in all 3 groups. Infection led to significantly increased levels of 
myeloid cells in all groups, but with Betamethasone and especially Indomethacin 
treatment, the percentage of CD33+ cells was higher. The granulocyte population 
was quite low and heterogenic, but a slight reduction could be detected in animals 
which received vehicle only compared to no change in treated animals (Fig. 25). 
After 7 days of moderate dose infection with GBS, the CD45+ cell population in the 
pb was basically unaffected in all groups. An increase in myeloid cells was also 
observed in all groups, but it was only significant in vehicle treated animals. 
Furthermore, the granulocyte population was also slightly bigger after infection in all 
animals, but only by tendency (Fig. 26).  
 
3.3.5 EFFECT OF TREATMENT ON HUMAN IMMUNE RESPONSE – 
CYTOKINE PRODUCTION 
 
Since treatment with Betamethasone and Indomethacin affected clearance of live 
bacteria and human immune cell populations, the effect of the drugs on the 
production and release of cytokines and chemokines, which serve as mediators of 
the immune response, was analyzed. Betamethasone reduced the amount of TNF, 
IFNγ and IL-6 in the bloodstream of high dose infected animals after 1 day (not 
significant). Indomethacin had no major effect at this time point (Fig. 27A). In the 
moderate dose infection model, 2 days post infection, Indomethacin induced 
significantly higher levels of the chemokine IL-8 in the serum. Treatment with both 
drugs also increased the level of IL-6 (not significant) (Fig. 27B). At day 3, the 
increased amount of IL-8 due to Indomethacin treatment was even more pronounced 
compared to day 2 in the moderate dose GBS infection model. Similar to day 2, the 
serum level of IL-6 was increased by both drugs (not significant) (Fig. 27C). 
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3.3.6 EFFECT OF TREATMENT ON HUMAN IMMUNE RESPONSE – NO 
PRODUCTION  
 
In order to test the capability of NO production of PEC in humanized mice, animals 
(n=6) were infected with 107 GBS to induce infiltration of leukocytes into the 
peritoneum. The infected mice were treated with vehicle (n=3) or Betamethasone 
(n=3) 3 h post infection. After 24 h, the PEC were extracted and restimulated in vitro 
by culturing them for 1 h and 24 h respectively with 107 GBS, again either with 
vehicle (n=3) or Betamethasone (n=3). The subsequent nitrite measurement 
revealed that no measurable amount of NO was produced by the PEC (data not 
shown). 
 
3.3.7 EFFECT OF TREATMENT ON DISEASE PROGRESSION – ORGAN 
DAMAGE 
 
Infection alone (vehicle treated animals) did not result in significant organ damage in 
our GBS infection models (high dose for 1 day, moderate dose for 3 or 7 days). 
Furthermore, Betamethasone or Indomethacin treatment did not seem to have an 
adverse effect, since treated animals also did not display organ damage 
(Supplement Fig 1-4 + data not shown). In conclusion, treatment did not cause or 
increase organ damage in the infection models analyzed in this study.  
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Fig. 27: Multiplex analysis of the concentration (pg/ml) of TNF, IFNγ, IL-1β, IL-6, IL-8 
and IL-10 in serum of infected animals treated with vehicle, (PBS), Betamethasone 
(BETA) or Indomethacin (INDO). Mice were either infected with 107 GBS, bled and 
tested after 1 day (A) or infected with 106 GBS and analyzed at day 2 (B) and 3 (C). 
Number of animals per group (n). Statistical analysis: Two-way ANOVA with Bonferroni 
posttest (*=p<0.05; ***=p<0.001). 
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3.4 EFFECTS OF TREATMENT IN VITRO 
 
Betamethasone or Indomethacin might exert a direct effect on the GBS itself, like 
facilitating growth, which would have increased their number in treated animals and 
led to the false assumption that the treatment reduced the clearance rate of the 
immune system (Fig. 17 B,C). To rule out a direct effect, 107 GBS were incubated 
either with vehicle alone (PBS), Betamethasone (1 µg/ml) or Indomethacin (1 µg/ml) 
for 4 h. In this timeframe, treatment did not significantly affect bacterial growth (Fig. 
28).  
 
 
 
 
 
 
In this study humanized mice were used as an animal model for the neonatal 
immune system. However, although the human immune cells in the animals feature 
similar deficiencies as neonatal leukocytes (see introduction), it was not certain, if 
genuine human neonatal immune cells behave similarly when challenged with GBS. 
Therefore, we also analyzed the bacterial clearance and the changes in immune cell 
populations of human neonatal MNC, isolated from cord blood, in vitro. 
To mimic the high dose infection model, 106 MNC were incubated for 4 h with 107 
GBS and either treated with PBS (vehicle), Betamethasone (1 µg/ml) or 
Indomethacin (1 µg/ml). The short timeframe was chosen to avoid bacterial 
overgrowth and death of the cultured MNC. At 4 h, bacterial clearance was 
unaffected by treatment (Fig. 29A). In order to incubate cord blood derived MNC 
together with GBS for extended periods of time, bacterial growth had to be abolished. 
To accomplish that, the bacteriostatic agent Chloramphenicol was used. Previous 
tests showed that the concentration of 2.5 µg/ml was high enough to completely 
inhibit bacterial growth but also low enough not to kill GBS at a density of 105/ml 
(Supplement Fig. 5). After 24 h of incubating MNC with GBS, Indomethacin treatment 
led to a reduced number of live bacteria, indicating increased bacterial clearance (not 
Fig. 28: Colony forming units (CFU) of 
107 GBS incubated alone for 4 h with 
either vehicle (PBS), 1 µg/ml 
Betamethasone (BETA) or 1 µg/ml 
Indomethacin (INDO). Statistical 
analysis: One-way ANOVA with Tukey 
posttest (no significant differences). 
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significant) (Fig. 29 B). However, after an incubation of 48 h, treatment with both 
drugs resulted in reduced bacterial clearance, though not significantly (Fig. 29C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
In our animal model we also analyzed the effect of treatment on leukocyte subsets 
with and without the presence of GBS. Therefore, cord blood derived MNC were 
either cultured alone or together with GBS and treated either with vehicle (PBS), 
Betamethasone (1 µg/ml) or Indomethacin (1 µg/ml). When cultivated with high 
doses of GBS (107) for 4 hours, a reduction of the total cell count mostly due to the 
lower number of CD33+ myeloid cells could be detected compared to the MNC that 
were cultured alone. An effect of drug treatment was not observed (Fig. 30A). 
Culturing of MNC with lower doses of GBS (105) for 24 h led to a markedly 
decreased total cell count because of the reduced number of T cells, myeloid cells 
and NK cells compared to MNC cultured alone. B cell count was relatively unaffected 
by the presence of live GBS. Treatment with both drugs led to an increased cell 
count in MNC incubated with GBS (not significant). No effect of treatment on the 
leukocyte subpopulations of the MNC that were cultured alone was observed (Fig. 
30B). After 48 h, presence of GBS also led to a reduced total cell count, again due to 
the lower number of T cells, myeloid cells and NK cells compared to MNC cultured 
Fig. 29: Colony forming units (CFU) of 107 GBS incubated with 106 MNC for 4 h and 
treated either with vehicle (PBS), 1 µg/ml Betamethasone (BETA) or 1 µg/ml 
Indomethacin (INDO) (A). CFU of 105 GBS incubated with 106 MNC for 24 h (B) or 48 h 
(C) with 2.5 µg/ml Chloramphenicol and treated either with vehicle (PBS), 1 µg/ml 
Betamethasone (BETA) or 1 µg/ml Indomethacin (INDO). Number of independent 
experiments (n); n=3 (A); n=2 (B,C). Statistical analysis: One-way ANOVA with Tukey 
posttest (no significant differences).  
B C 
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without GBS. Furthermore, only treatment with Indomethacin resulted in higher total 
cell count (not significant). In the MNC cultured alone for 48 h, the total cell count 
was reduced compared to MNC cultured alone for 24 h. This was mostly caused by 
the reduced number of granulocytes. Interestingly enough, treatment with 
Betamethasone led to a reduced total cell count due to a reduction in the number of 
T cells (not significant) (Fig. 30C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 30: Flow cytometric analysis of CD3+ T cells, CD33+ myeloid cells, CD66+ 
granulocytes and CD56+ NK cells of cord blood derived MNC (106) incubated without 
and with 107 GBS for 4 h (A). Flow cytometric analysis of CD3+ T cells, CD19+ B cells, 
CD33+ myeloid cells, CD66+ granulocytes and CD56+ NK cells of 106 MNC incubated 
without and with 105 GBS plus 2.5 µg/ml Chloramphenicol for 24 h (B) and 48 h (C). 
MNC were either treated with vehicle (PBS), 1 µg/ml Betamethasone (BETA) or 1 µg/ml 
Indomethacin (INDO). Number of independent experiments (n); n=3 for all incubations 
of MNC without GBS, n=3 for incubation of MNC with GBS for 4 h; n=2 for incubation of 
MNC with GBS for 24 h and 48 h. Statistical analysis: Two-way ANOVA with Bonferroni 
posttest (no significant differences detected). 
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4  DISCUSSION 
4.1 HUMANIZED MICE AS A GBS INFECTION MODEL 
 
In this study I introduce a new model for GBS sepsis in neonates and analyzed the 
effect of Betamethasone and Indomethacin treatment in an ongoing bacterial 
infection. Only in vivo models allow the investigation of complex processes that occur 
during infection, like disease progression, clearance of bacteria in different organs, 
organ damage, leukocyte migration, hematopoiesis and the effect of treatment on 
these processes. Therefore, infection and sepsis studies are usually conducted using 
mice as an animal model since there are severe ethical as well as legal constraints 
for using human subjects (Shultz et al. 2007). However, although the mouse is a 
valuable research tool, there are more than 60 known differences in the immune 
system between mice and men (Mestas & Hughes 2004). Especially in sepsis, these 
differences seem to play an important role, since therapeutic treatments which have 
worked in animal studies failed in more than 25 clinical trials (Unsinger et al. 2009).  
In order to combine the human immune system together with an in vivo model, the 
humanized mouse model was used for these experiments. Humanized mice feature 
all human immune cell subsets including granulocytes, monocytes/macrophages, 
plasmacytoid and myeloid DCs, NK, T and B cells as well as human erythrocytes and 
platelets (Ishikawa et al. 2005; Shultz et al. 2005; Shultz et al. 2007, Unsinger et al. 
2009). Therefore the pathogen (GBS) interacts with human leukocytes, and the 
response of a human immune system can be analyzed. The second benefit of 
humanized mice is heterogeneity. Animals used in sepsis models are genetically 
identical from inbred strains and generally of the same sex, whereas human patients 
are of both sexes and genetically heterogenic. This could be one of the reasons why 
translating the results of animal studies of sepsis poses a problem (Pitts & Simpson 
2010). I used mice as well as cord blood from both sexes. And since the cord blood 
for transplantation also stems from various human donors, the genetic heterogeneity 
is also ensured. Heterogeneity is also visible in the amount of leukocytes and 
immune cell subsets in the humanized mice (Fig. 2), which coincides at least 
basically with the broad leukocyte ranges of human neonates (Ikincioğullari et al. 
2004). Due to the heterogeneity of the animals, significant differences due to 
infection and treatment are less frequent than in inbred animals. However, the results 
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from this study are probably more relevant and can be transferred onto humans more 
easily.  
The first aim of this study was to analyze the distribution of human immune cells in 
the organs of humanized mice. This was done to ensure that leukocytes are present 
in lymphoid as well as other relevant organs and also to be able to compare the 
entire immune system of humanized mice and human neonates or adults. A direct 
comparison of leukocytes and leukocyte subsets in humanized mice and humans 
(adults and neonates) revealed that the relative size of B and T cell populations is 
similar in most organs (supplementary table 2-6). However, tissue macrophages in 
the lung and peritoneum and granulocytes in the pb and BM are underrepresented in 
the animal model, due to a lack of species-specific hematopoietic growth factors and 
a mouse microenvironment which seems to be suboptimal for human hematopoiesis, 
especially for the development of the myeloid linage (Shultz et al. 2007; Andre et al. 
2010; Gille et al. 2012). Considering the important role of granulocytes and 
macrophages in fighting off bacterial infections, these differences can be seen as 
less-than-ideal for this model. However, to put this fact into perspective, even though 
there might be fewer myeloid cells present in humanized mice, these cells are 
functional. We could show that in vitro generated BMDM not only displayed a 
morphology similar to human donors (Möst et al. 1997) but also expressed the 
maturation marker CD86 after stimulation. Tanaka et al. recently showed that also 
the phagocytic activity and bacterial killing of BMDM of humanized mice are 
comparable to that of human macrophages (Tanaka et al. 2012).  
Although humanized NSG mice feature a functional human immune system, they still 
possess a residual mouse immune system. However, due to the fact that 10/11 
irradiated NSG mice died whereas all their humanized littermates survived the GBS 
infection (Fig. 8), there is a good case to believe that the remnants of the mouse 
immune system do not play a major role in resolving GBS infection. In addition the 
murine immune system of NSG mice lacks mature B, T and NK cells, the 
macrophages feature an immature phenotype, the DC are deficient and they also 
lack complement lysis due to a functional impairment of the complement factor C5 
(Shultz et al. 1995; Türeci et al. 2003; Serbina et al. 2003; Shultz et al. 2005; Shultz 
et al. 2007).  
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In the first part of my thesis, I determined if the humanized mouse represents a 
suitable model for GBS infection. Our results revealed considerable reconstitution of 
human leukocytes in all analyzed organs, dose dependent survival and disease 
progression and that the residual mouse immune cells did not play a major role in 
resolving the GBS infection. This makes humanized mice the closest human like 
animal model currently available to study GBS infection and treatment effects in vivo. 
 
4.2 EFFECTS OF GBS INFECTION IN HUMANIZED MICE 
 
The second aim of this thesis was to analyze the effects of GBS infection on 
humanized mice and their human immune system (organ damage, changes in 
leukocyte populations due to proliferation and migration, cytokine production etc.). In 
the following paragraph I compare the changes in leukocyte subsets to humans and 
neonates (if possible), or other animal models in order to determine if the human 
immune system in humanized mice reacts to GBS infection (or bacterial infection in 
general) in a similar manner as the human (neonatal) immune system or a fully 
functional immune system of animal models. 
 
4.2.2 ORGAN DAMAGE 
 
In both the high dose (after 1 day) and the moderate dose infection model (after 3 
and 7 days), no organ damage was detected. Since GBS is a major pathogen 
causing neonatal meningitis (Palys et al. 2006) we expected pathological changes in 
the brain. Studies using mice as an animal model for meningitis show that brain 
damage is accompanied by massive amounts of bacteria in the brain (2x108-1x1010 
CFU) (Mook-Kanamori et al. 2012). Infected humanized mice displayed considerably 
lower CFU counts (< 1x106), which might explain the absence of organ damage in 
the brain. The hypothesis that high amounts of live bacteria are necessary to induce 
organ damage in humanized mice is supported by the fact that high dose infected 
animals, which displayed pathological changes in lung and spleen after 2 days of 
infection (Fig. 9) also featured high amounts of GBS in both organs (>6x108). The 
organ damage was also most likely responsible or contributed majorly to the high 
mortality in the high dose infection model. 
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4.2.3 CHANGES IN LEUKOCYTE POPULATIONS AND CYTOKINE PROFILE 
 
T cells 
Based on the literature, both humanized mice and human neonates feature very 
similar deficiencies. Since the amniotic cavity resembles a sterile environment, the 
majority of human neonatal T cells feature a naïve phenotype, which was also 
observed in CD4+ and even more so in CD8+ T cells in spleen, pb and lung of 
uninfected humanized mice. This was most likely caused by the specific pathogen 
free environment the mice were kept and bred in. Human neonatal T cells also 
express low amounts of IL-4 as well as IFN-γ upon activation and show lower 
proliferation compared to adult T cells, which is most likely attributed to their lower 
production of IL-2 (Schelonka & Infante 1998; Chalmers et al. 1998; Watson et al. 
1991; Gasparoni et al. 2003).  
Infected humanized mice did not display major changes in T cell populations except 
an increase in T cells in the pb after 1 day. That indicates a problem in the T cell 
function. Upon activation, T cells in humanized mice are known to produce low 
amounts of IFNγ, IL-4 and also IL-2 which corresponds well with their reduced 
proliferation (Watanabe et al. 2009). The reduced proliferation after antigenic 
stimulation could be one of the reasons why there was basically no increase in T cell 
numbers in infected humanized mice. To exacerbate the reduced proliferation 
capabilities, T cells in humanized mice are positively selected in the mouse thymus, 
and therefore have problems recognizing human MHC molecules (Watanabe et al. 
2009). Another factor contributing to the reduced proliferation and T cell function in 
humanized mice are species specific cytokines produced by non-leukocyte cells. IL-7 
is essential for T, B and dendritic cell development and also important for T cell 
homeostasis. It is produced primarily by stromal cells in thymus and bone marrow 
(Dittel & LeBien 1995; von Freeden-Jeffry et al. 1997; El Kassar et al. 2004; 
Mazzucchelli et al. 2004; Vogt et al. 2009). For survival and homeostatic proliferation 
of CD8+ cytotoxic T cells, IL-15 is required (Surh & Sprent 2008). The combination of 
all these factors likely is the reason for the absence of proliferation of T cells in this 
infection model. There was also a lack of T cell migration in infected animals, which 
could have been caused or aggravated by a lack of human-specific chemokines and 
adhesion molecules in humanized mice (Macchiarini et al. 2005; Shultz et al. 2007).  
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B cells 
According to the literature, human neonatal B cells share a variety of defects with 
their counterpart in humanized mice. Studies found that B cells from humanized mice 
mostly feature a naïve phenotype (CD5+) and produce lower amounts of IgM and 
especially IgG, which most likely stems from a lack of germinal center formation and 
class switch (Lepus et al. 2009; Watanabe et al. 2009; Rajesh et al. 2010). Similar to 
humanized mice the naïve phenotype is also dominant in human neonatal B cells. 
They not only produce low amounts of Ig, these cells also mainly produce IgM and 
only little IgG and IgA after stimulation (Schelonka & Infante 1998; Splawski et al. 
1991). Furthermore, animal studies have shown that structures, which are needed for 
B cell activation and antibody production against T cell dependent antigens, are 
missing at birth (Adkins et al. 2004), which implies that human neonates also lack 
germinal centers, which is similar to the situation in humanized mice.  
Unlike T cells, B cells displayed both considerable proliferation and migration. After 1 
day of GBS infection the CD19+ B cells in spleen and BM increased while 
simultaneously decreasing in the pb (Fig. 11,13). After 3 days, a decrease in the pb 
coupled with an increase in the spleen was detected. Since other organs (liver, lung 
and peritoneum) were not affected, the logical explanation would be that the B cells 
migrated from the blood into the lymphoid structures (spleen and BM). A major 
contributing factor for the increase in B cells in the spleen after 3 days (possibly even 
after 1 day in BM and spleen) might have been proliferation. While fetal 
hematopoiesis takes place in the liver and spleen, the BM is the major site of 
hematopoiesis in adults. Although under certain conditions like irradiation, 
inflammation or infection with certain pathogens, extramedullary hematopoiesis, 
usually in spleen and liver, can occur. Lymphopoiesis and therefore B cell production 
in the BM is usually reduced in favor of increased myelopoiesis, especially 
granulopoiesis, which would explain the equal levels of B cells in animals infected for 
3 days and in uninfected mice. However, extramedullary B cell lymphopoiesis can 
take place in the spleen, which might have been a contributing factor for the 
increased number of B cells on day 3 of GBS infection. The increase in 
hematopoiesis can be explained by the binding of TLR ligands (e.g. GBS cell wall 
components) to TLR on hematopoietic progenitors. (Tagaya et al. 2000; Nagai et al. 
2006; Cain et al. 2009; Kim 2010; Bockstal et al. 2011). An additional contributing 
factor for the increased B cell count, 3 days post infection could have been TI 
activation and proliferation by mitogens. Peptidoglycan (part of the cell wall of GBS) 
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is a known TI antigen which induces proliferation and antibody production in B cells 
(Dziarski 1982; Caliot et al. 2012).  
 
Myeloid cells 
Human neonatal monocytes/macrophages display a reduced ability to kill GBS, and 
produce a lower amount of the cytokines IL-1β and IL-6 upon stimulation. Neonatal 
DC produce lower amounts of IL-12 and also feature reduced phagocytic activity 
(Pillay et al. 1994; Goriely et al. 2001; Liu et al. 2001; Marodi 2006). Although, the 
number of myeloid cells in humanized mice is generally limited, the phagocytic 
activity and bacterial killing of macrophages is comparable to their human 
counterpart (Andre et al. 2010, Tanaka et al. 2012). Furthermore, a direct 
comparison of monocytes from humanized NSG mice with neonatal human 
monocytes from cord blood revealed that phagocytic activity was identical and that 
basal expression of costimulatory molecules and the capacity to induce T cell 
proliferation was similar (Gille et al. 2012).  
In this study, CD33+ myeloid cells decreased in the BM, but increased in pb, spleen 
and liver at all three time points by tendency (Fig. 11,13). This suggests the migration 
of myeloid cells (predominantly monocytes) from the BM into the pb (transport 
medium) from where they were recruited into the organs to contain and combat the 
infection (Luster et al. 2005). Monocytes are generated from progenitor cells in the 
BM, which also serves as a reservoir from which monocytes are mobilized. Upon 
inflammation, mostly inflammatory monocytes emigrate into the bloodstream. At the 
site of infection, monocytes transmigrate into the inflamed tissue and can 
differentiate into TNF- and iNOS-producing (TIP) DC or classically activated 
macrophages. This recruitment of inflammatory monocytes is essential for efficient 
clearance of pathogens. Interestingly enough, the liver and the spleen, which 
represent the two organs to which CD33+ cells were trafficking in the infected 
humanized mice, are also the sites where inflammatory monocyte recruitment is 
necessary to control the early stages of infection with Listeria monocytogenes, also a 
gram-positive bacterium. (Rosen et al. 1989; Serbina et al. 2003; Swirski et al. 2009; 
Shi et al. 2010; Shi & Pamer 2011).  
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Granulocytes 
Granulocytes, mostly comprised of neutrophils, are also referred to as the first line of 
defense, since they are the first leukocytes recruited to the site of infection to kill 
bacteria (Yoshio et al. 2004). Chemotaxis, movement speed and bactericidal activity 
are decreased in neonatal neutrophils (Anderson et al. 1991; Wolnach et al. 1998). 
Studies in rats and circumstantial evidence from human neonates suggest that the 
neutrophil storage pool in the BM of neonates is not only smaller, but also that 
granulopoiesis during infection is reduced, leading to a rapid exhaustion of the 
storage pool compared to adult individuals (Christensen et al. 1982; Christensen 
1989; Carr & Modi 1997).  
The CD66+ granulocyte count in uninfected humanized mice was rather low 
(6x105/femur) compared to neonatal rats (>1x107/femur) or human adults (estimated 
total of 6x1011). Also in the pb the population is quite small with <1% in humanized 
mice compared to 50-70% in humans (Mestas & Hughes 2004). In contrast to CD33+ 
cells, the duration of infection had a marked effect on the granulocyte populations in 
humanized mice. During the infection, the granulocyte population increased up to 
255% (compared to uninfected animals) on day 3 (Fig. 11), which was most likely 
caused by increased granulopoiesis due to the GBS infection. A similar effect can 
also be observed in human adults where granulocyte production is increased by 
more than 300% during sepsis (Carr & Modi 1997). It is known from animal models of 
GBS infection that the number of granulocytes significantly increases in the BM as 
well as the pb (Christensen et al. 1982; Furze & Rankin 2008). While granulocyte 
numbers increased in the BM of infected humanized mice, a marked increase in the 
pb or in other organs was not detected on day 1, 3 and 7. On one hand, this could 
mean that the increase in the pb occurred at a time-point which was not analyzed 
since there is only a certain timeframe where granulocytes are elevated in the pb in 
the animal model. The other option is that the cytokines and chemokines needed for 
the neutrophil release from the BM were not present in the necessary concentrations 
or that the neutrophils themselves feature deficiencies which keep them from exiting 
the BM. These defects, in combination with the low numbers of granulocytes in the 
BM also explain the low amount of circulating granulocytes in the pb.  
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Cytokine profile in infected animals 
Cytokines are small immunomodulatory proteins and peptides, produced by a variety 
of cells. They play essential roles in host defense, wound healing and have several 
other functions. While cytokines are important for homeostasis, excessive production 
and systemic release result in systemic inflammation and organ dysfunction, causing 
sepsis. In high dose infected humanized mice, high levels of the cytokines TNF, 
IFNγ, IL-1β, IL-6, IL-8 and IL-10 were detected after 1 day, which matched or even 
exceeded the maximum concentration in the serum of adult humans with severe 
sepsis. Compared to septic neonates, the cytokine levels of TNF, IL-1β, IL-6 and IL-8 
in high dose infected animals exceeded mean or maximum human levels by far (Kurt 
et al. 2007; Lvovschi et al. 2011). This indicates that the high dose infected 
humanized mice indeed developed GBS sepsis on day 1. While the moderate dose 
infected animals did not display excessive cytokine production, the serum levels of 
IL-1β, IL-10 and IL-8 were still within range of septic adults (Lvovschi et al. 2011). 
The connection between the cytokines TNF, IL-1β, IL-6 and IL-8 and sepsis is very 
pronounced. TNF can cause organ dysfunction and induce systemic inflammatory 
response syndrome (SIRS) when injected into human subjects (Chapman et al. 
1987). Injection of IL-1β also induces SIRS symptoms (Blackwell & Christman 1996). 
IL-6 has been indicated as a good prognostic marker for organ dysfunction and death 
in septic humans, although the exact role in sepsis is still unclear due to varying 
results in animal studies. High levels of IL-8 can lead to tissue injury by activated 
neutrophils and therefore indicate increased mortality in sepsis. IL-10 is an anti-
inflammatory cytokine which is elevated in patients with septic shock (Creasey et al. 
1991; Blackwell & Chrisman 1996; Remick et al. 2005).  
 
The second part of my thesis shows that human neonatal immune cells and their 
counterparts in humanized mice share various deficiencies, which indicates that their 
immune system, as well as the responses of their immune system, are most likely 
comparable. Based on serum cytokine levels, the high dose infection model is a well 
suited GBS sepsis model, reflecting the situation in septic human adults and 
neonates. While the moderate dose infection model only partially resembles the 
situation in humans suffering from severe sepsis, this model allows the analysis of 
longer term effects of GBS infection on the human immune system. These findings 
indicate that the humanized mouse is a useful tool for investigating new therapies, 
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test the effect of new therapeutic agents as well as optimizing already existing 
therapies for human neonatal GBS infections.  
 
4.3 EFFECTS OF TREATMENT ON AN ONGOING GBS 
INFECTION IN HUMANIZED MICE 
 
In the third part of my thesis this new animal model was used to determine the effect 
of the two drugs Betamethasone and Indomethacin on a naïve human (neonatal) 
immune system during an ongoing GBS infection. 
 
4.3.1 EFFECTS OF BETAMETHASONE TREATMENT 
 
Corticosteroids are divided in glucocorticoids and mineralocorticoids which bind to 
glucocorticoid receptors and mineralocorticoid receptors to exert their effects in cells 
(Rickard & Young 2009). Glucocorticoids are among the most prescribed drugs 
worldwide, and known for their pronounced anti-inflammatory effects, which are 
caused by increasing the expression of anti-inflammatory proteins, inhibition of 
proinflammatory gene activation and induction of apoptosis in thymocytes, 
lymphocytes and also monocytes (Necela & Cidlowski 2004; Busillo et al. 2011).  
However, after 1 day of infection Betamethasone treatment reduced the systemic 
bacterial burden and also the CFU count in the peritoneum (Fig. 17). This effect 
might be explained by increased clearance due to the slightly higher number of 
granulocytes, (Fig. 20). While glucocorticoids exert immunosuppressive effects 
especially on cellular immune responses, these drugs also have the ability to boost 
the innate immune system. Glucocorticoids have been shown to increase 
granulopoiesis and inhibit neutrophil apoptosis, leading to increased numbers of 
circulating granulocytes. They also can enhance phagocytic and bactericidal activity 
in macrophages, which might have been a contributing factor here. (Inada et al. 
1988; Meagher et al. 1996; van der Goes et al. 2000; Schleimer 2004).  
After 1 day of high dose infection Betamethasone treatment did only induce slight 
reductions in TNF, IFNγ and IL-6 levels of the analyzed cytokines (Fig. 27). Based on 
the literature, glucocorticoid treatment should have reduced the serum 
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concentrations of all analyzed cytokines (IFNγ, TNF, IL-1β, IL-6, IL-8 and IL-10) 
(Brattsand & Linden 1996; Wiegers & Reul 1998). However, what most studies do 
not take into account is the fact that there are several pitfalls concerning the effect of 
glucocorticoids on immune responses. First of all, a variety of in vitro studies used 
corticosteroid concentrations that are unobtainable in vivo, at least not for a 
significant amount of time. Furthermore, most in vivo studies were conducted using 
mice, rats and rabbits, which are all corticosteroid-sensitive species where the effects 
of treatment are more pronounced than in corticosteroid-resistant species which 
include humans (Parrillo & Fauci 1979). This example illustrates the usefulness of 
the humanized mouse as an in vivo model, since here the effect of treatment varies 
between conventional animal models and humans. Two and also 3 days after 
moderate dose infection, administration of Betamethasone had no pronounced effect 
on cytokine production. It is interesting though, that in both Betamethasone and 
Indomethacin treated animals IL-6 levels were elevated (not significantly) probably 
due to the presence of higher amounts of GBS. As described above, (4.2.3) IL-6 is 
the only cytokine considered a reliable prognostic marker for sepsis since its serum 
level correlates well not only with severity of bacterial infection but also with mortality 
in human patients (Damas et al. 1992). This effect, coupled with the significantly 
increased systemic CFU count in glucocorticoid treated animals indicates that 
administration of Betamethasone increases the severity of GBS infection and should 
therefore be combined with antibiotic treatment in the clinic to reduce the bacterial 
burden in the infant.  
Glucocorticoids are known for their inhibition of lymphocyte proliferation and 
induction of apoptosis. The major mechanism is inhibition of the production of IL-2, 
which stimulates the proliferation of T and B cells (Mingari et al. 1984; Horst & Flad 
1987; Auphan et al. 1995). The inhibition of IL-2 production by Betamethasone could 
play a role in the significant reduction of B and T cells in the spleen of humanized 
mice, after 3 days of infection (Fig. 21). This explanation accounts for the changes in 
the B cell population, since infection induced a significant increase of this cell type in 
the spleen after 3 days (Fig. 11). However, T cells were not elevated due to infection, 
implicating a lack of proliferation. The reduction in T cells in the spleen after 
Betamethasone treatment might be due to apoptosis, since glucocorticoids are also 
known for inducing cell death in immature T cell precursors and mature T cells 
(Sapolsky et al. 2000). The increase in B cells in the BM of Betamethasone-treated 
animals cannot be explained by a direct effect of glucocorticoids. A possible 
explanation is the migration of B cells from the spleen into the BM, however it is more 
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likely that this effect was cause by increased B cell hematopoiesis in the BM induced 
by higher amounts of bacterial products due to the increased GBS titers in 
Betamethasone-treated animals (Fig. 17). Monocytes significantly decreased in the 
BM due to Betamethasone treatment, 3 days post infection (Fig. 21). An explanation 
could be the apoptosis inducing effect of glucocorticoids on monocytes (Necela & 
Cidlowski 2004). The reduction in monocytes is probably one of the main reasons 
why treatment with Betamethasone resulted in systemically elevated GBS counts 3 
days post infection (Fig. 17). Another interesting finding after glucocorticoid treatment 
was the presence of GBS in the brain after 3 days in 3/10 animals, which was absent 
in untreated controls (Fig. 18). While this effect is not significant, it indicates that 
glucocorticoid administration increases the likelihood of GBS entering the brain which 
in turn increases the risk of brain damage. 
The Betamethasone-induced changes in leukocyte subpopulations were far less 
pronounced after 7 days compared to 3 days of infection. The reason was most 
probably the absence of considerable glucocorticoid levels in the circulation. 
Betamethasone has a plasma half-life of 6.5 – 9 h and a biological half live (duration 
of measurable biological activity) of 36 – 54 h (Tegethoff et al. 2009). Therefore, both 
after day 1 and 3 of infection, relevant glucocorticoid levels should have been 
present systemically leading to the above mentioned effects. With declining serum 
levels and waning biological activity of Betamethasone, the immune system of 
infected humanized mice was most likely able to cope with the infection, resulting in 
similar CFU counts and immune cell populations after 7 days in treated and 
untreated animals.  
 
4.3.2 EFFECTS OF INDOMETHACIN TREATMENT 
 
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) and often used to 
reduce fever, pain, stiffness and swelling. It is called a "short-acting" NSAID because 
of the relatively short plasma half-life (5-10h) in adult humans, which is prolonged in 
neonates (11–36h) (Brash et al. 1981; Helleberg 1981). By inhibiting PG (especially 
PGE2) production, Indomethacin affects both cellular and humoral immune 
responses and inflammation. Similar to glucocorticoid treatment, Indomethacin had 
no pronounced effects on cytokine production after 1 day of high dose GBS infection. 
However, not only did it induce a slight increase in IL-6 (not significant), it also led to 
an increase in IL-8 both after day 2 and 3 in the moderate dose infection model. This 
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specific chemokine not only attracts neutrophils, it also augments their bactericidal 
activity by inducing respiratory burst and ROS production among other functions. 
Neutrophils can cause oxidative tissue damage when eliminating pathogens and 
several studies have shown that the number of neutrophils correlates with vascular 
damage and tissue damage leading to decreased organ function and even organ 
failure (Partrick et al. 1996; Mukaida et al. 1998; Brown et al. 2006). Although 
Indomethacin increased IL-8 levels in infected humanized mice, this effect did not 
lead to an increase of neutrophils in the pb or other organs (Fig. 21). As discussed 
above (4.2.3), this most likely stems from a lack of species specific factors, needed 
for the emigration from the BM, and/or deficient granulocytes in the humanized 
mouse model. However, this finding indicates that in GBS infected neonates, where 
emigration of neutrophils from the BM is unimpaired, an increase in IL-8 induced by 
Indomethacin could lead to elevated numbers of neutrophils in the pb and organs 
which in turn might cause, or increase organ damage.  
Indomethacin induced a reduction in T as well as B cells in the spleen 3 days after 
infection (Fig. 21). The decrease in B cells can be explained by the ability of 
Indomethacin to reduce B cell proliferation (Rojo et al. 1981). Due to the fact that in 
untreated animals proliferation most likely caused the increase in B cell numbers in 
the spleen 3 days post infection (Fig. 11), Indomethacin–induced abrogation of 
proliferation explains the observed reduction in B cell numbers. Since T cells did not 
increase in the spleen of untreated animals, inhibition of proliferation by 
Indomethacin does not explain the decrease in treated animals. However studies 
have shown that Indomethacin does induce the expression of Nur77, which induces 
T cell apoptosis (Kang et al. 2000; Tao & Hancock 2008), explaining the reduction in 
splenic T cells. 
Other changes in leukocyte subpopulations (B cells and myeloid cells) as well as the 
increase in systemic CFU count after 3 days of infection were present only by 
tendency after treatment with Indomethacin but correlate well with the findings in the 
glucocorticoid treatment group. Similar to Betamethasone, administration of 
Indomethacin resulted in the presence of live GBS in the brain of some (2/10) 
animals (Fig 18). In regard to these findings, Indomethacin treatment should also be 
combined with antibiotics to reduce the bacterial burden in the infants and also 
reduce the risk of brain damage.  
After 7 days of moderate dose infection, no major changes due to Indomethacin 
treatment were detected. This most likely stems from the short half-live of 
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Indomethacin, which in turn led to low circulating concentrations, and therefore no 
major effect of this drug 5 days after the last injection.  
 
In summary, both drugs affect the human immune system and disease progression 
in GBS infected humanized mice. While administration of Betamethasone initially 
decreases the systemic CFU count, glucocorticoid treatment causes adverse effects 
during prolonged GBS infection. After 3 days, Betamethasone leads to a reduction in 
lymphocytes and myeloid cells, which is accompanied by a systemic increase in 
CFU. At this time point, Indomethacin also causes a decrease in lymphocytes, which 
is also combined with an increased bacterial burden. Due to relatively short plasma 
half-lives, both drugs do not exert major long term effects on human immune cell 
populations and leukocyte function (7 days post infection). Based on the fact that 
both Betamethasone and Indomethacin treatment increase the bacterial burden and 
also seem to facilitate the infiltration of GBS into the brain, both drugs should be 
combined with antibiotics to reduce the amount of bacteria, which in turn should 
reduce or might even prevent organ damage, especially brain involvement. 
 
4.4 EFFECTS OF TREATMENT ON HUMAN CORD BLOOD 
DERIVED MNC IN VITRO 
 
In the last part of my thesis I performed in vitro experiments using neonatal (cord 
blood derived) MNC and analyzed the effect of Betamethasone and Indomethacin on 
human leukocytes with and without the presence of live GBS as well as the effect of 
treatment on GBS alone. In the following paragraph these findings are compared 
with the results obtained from the in vivo studies on infected and treated humanized 
mice. This is done to determine if leukocytes from neonatal humans (cord blood) and 
immune cells in humanized mice behave similarly when challenged with GBS and 
treated with either drug. 
None of the findings in vitro were significant, and are therefore only discussed briefly. 
Since both Betamethasone and Indomethacin affected the CFU count in humanized 
mice, it was important to determine if this was caused by an effect of both drugs on 
leukocytes which then altered bacterial clearance or if it was a direct effect of 
treatment on the growth of GBS. Since neither drug showed a marked impact on 
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bacterial growth (Fig. 28) it is safe to assume that the effect on the CFU count in vivo 
stems from effects that both drugs exert on immune cells. 
In vitro Betamethasone and Indomethacin treatment resulted in reduced bacterial 
clearance by the human MNC after prolonged cultivation (2 days), which was also 
observed in vivo (3 days). Interestingly enough, the positive effect of glucocorticoids 
on bacterial clearance which was observed in vivo after 24 h of infection was not 
present in vitro. This probably stems from the fact that certain glucocorticoid-
mediated effects, like the enhancement of granulocyte efflux from the bone marrow, 
only play a role in vivo. 
The effects of treatment during infection (presence of GBS) on leukocyte subsets 
observed in vivo were either less pronounced in vitro or absent altogether. However, 
this is not necessarily an indicator that the humanized mouse is a less-than-ideal 
model for the neonatal immune system. In fact, it much more implies that the 
complex mechanisms, involved in the immune response and the effects of treatment 
on those processes, cannot be sufficiently studied in vitro. Hematopoiesis, release of 
leukocytes (mainly granulocytes and monocytes) from storage pools, leukocyte 
trafficking and proliferation, but also dissemination of bacteria in the body, plasma 
clearance of drugs, those are all examples why an animal model is vital to study 
infectious diseases and the effect or efficacy of treatment. 
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5  SUMMARY & OUTLOOK 
 
In this thesis I generated a novel animal model for GBS infection using humanized 
mice and investigated the effect of Betamethasone and Indomethacin on their naïve 
and deficient human immune system, which resembles that of human neonates quite 
well. The results not only showed that both drugs induced changes in B, T and 
myeloid cell populations, treatment also led to an increased bacterial burden. This 
increase in CFU enhances the risk (or the severity) of organ damage, especially in 
the brain where GBS was only detected after treatment. These findings suggest, that 
when Betamethasone or Indomethacin are used in perinatal care and a bacterial 
infection is present, they should be given in combination with antibiotics due to the 
adverse effects of both drugs on bacterial clearance.  
This new GBS infection model allows for the investigation of the effects of other 
drugs and treatment options on various parameters (e.g. bacterial clearance and 
immune cell trafficking) in a naïve and neonatal-like human immune system. To 
further improve the animal model, the use of a more aggressive, clinically relevant 
GBS strain should be taken into consideration. This should enable the investigation 
of treatment on organ damage which was not present in my infection model, most 
likely due to the use of a less aggressive GBS reference strain.  
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Supplement Fig. 1: Immunohistochemical staining for CD45+ leukocytes in spleen, liver, 
lung, mLN of uninfected (no INF), vehicle (PBS)-, Betamethasone (BETA)- and 
Indomethacin (INDO)-treated humanized mice. Animals were infected with moderate 
doses of GBS (106) and analyzed at day 3. Black bar = 100µm, objective used 40x.  
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Supplement Fig. 2: Immunohistochemical staining for CD3+ T cells in spleen, liver, lung, 
mLN of uninfected (no INF), vehicle (PBS)-, Betamethasone (BETA)- and Indomethacin 
(INDO)-treated humanized mice. Animals were infected with moderate doses of GBS 
(106) and analyzed at day 3. Black bar = 100µm, objective used 40x.  
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Supplement Fig. 3: Immunohistochemical staining for CD79a+ B cells in spleen, liver, 
lung, mLN of uninfected (no INF), vehicle (PBS)-, Betamethasone (BETA)- and 
Indomethacin (INDO)-treated humanized mice. Animals were infected with moderate 
doses of GBS (106) and analyzed at day 3. Black bar = 100µm, objective used 40x.  
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Supplement Fig. 4: Immunohistochemical staining for CD68+ macrophages in spleen, 
liver, lung, mLN of uninfected (no INF), vehicle (PBS)-, Betamethasone (BETA)- and 
Indomethacin (INDO)-treated humanized mice. Animals were infected with moderate 
doses of GBS (106) and analyzed at day 3. Black bar = 100µm, objective used 40x. 
Supplement Fig. 5: Two concentrations of GBS, 105/ml (A) and 106/ml (B) were 
incubated with different concentrations of the bacteriostatic agent Chloramphenicol: no 
Chloramphenicol (vehicle PBS), 2.5 µg/ml, 5.0 µg/ml, 10 µg/ml and 15 µg/ml.  
A B 
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Supplement Table 1: CFUs in organs of individual humanized mice infected with GBS  
CFUs of individual animals (n=10) after 1 day of high dose infection (10
7
 GBS) 
spleen 1.6x10
6
 0 1.2x10
8
 2.2x10
8
 8.6x10
5
 4.9x10
7
 0 0 4.1x10
8
 7.0x10
7
 
kidney 4.5x10
6
 4.0x10
3
 2.8x10
7
 3.2x10
7
 2.6x10
6
 1.9x10
7
 0 4.3x10
4
 1.2x10
8
 3.1x10
7
 
liver 1.2x10
6
 0 5.7x10
7
 6.7x10
7
 6.7x10
5
 8.6x10
6
 0 0 1.2x10
8
 4.3x10
7
 
lung 5.0x10
7
 1.1x10
3
 1.4x10
8
 8.2x10
7
 6.9x10
6
 3.8x10
7
 0 0 7.9x10
7
 7.7x10
6
 
brain 7.2x10
4
 0 0 1.6x10
5
 1.6x10
5
 2.1x10
5
 0 0 5.7x10
5
 1.7x10
5
 
BM 1.8x10
4
 1.8x10
3
 8.0x10
5
 1.9x10
6
 0 2.8x10
5
 4.0x10
4
 0 4.0x10
6
 1.0x10
5
 
peritoneum 1.1x10
7
 0 4.4x10
8
 3.1x10
8
 0 1.5x10
8
 0 0 2.3x10
9
 4.3x108 
 
CFUs of individual animals (n=6) after 7 days of moderate dose infection (10
6
 GBS) 
spleen 0 0 0 0 0 0 
kidney 0 0 0 0 0 2.5x10
7 
liver 0 0 0 0 0 76 
lung 0 1.3x10
3 
0 0 0 0 
brain 0 0 0 0 0 0 
BM 0 0 0 0 0 2.0x10
2 
peritoneum 0 4.3x10
3 
0 0 0 0 
 
Supplement Table 2: Relative amounts (%) of human leukocyte subsets in the pb 
 
lympho-
cytes
# 
B 
cells
#
 
T 
cells
# 
CD4
+
 
T cells
# 
CD8
+
 
T cells
# 
myeloid 
cells
§ 
granulo-
cytes
§ 
humanized 
mouse 
33 
(27-44) 
44 
(31-60) 
56 
(40-70) 
62 
(57-69) 
35 
(30-41) 
7 
(±3) 
0.06 
(±0.15) 
cord blood 
41 
(35-47) 
20 
(14-23) 
55 
(49-62) 
35 
(28-42) 
29 
(26-33) 
11 
(±17) 
47 
(±25) 
adult 
32 
(28-39) 
13 
(11-16) 
72 
(67-76) 
42 
(38-46) 
35 
(31-40) 
3-9 
- 
50-72 
- 
#Values represent the median, ranges from 25th to 75th percentiles in parentheses. Values 
of cord blood and adult pb (Erkeller-Yuksel et al. 1992). §Values represent the mean ± 
standard deviation in parentheses. Values of cord blood and adult pb (Katsares et al. 2009). 
CFUs of individual animals (n=10) after 3 days of moderate dose infection (10
6
 GBS) 
spleen 0 0 0 0 0 0 0 0 5.0x10
3
 0 
kidney 0 0 0 6.0x10
4
 0 0 0 0 0 0 
liver 0 0 0 1.9x10
2
 1.8x10
2
 2.9x10
3
 0 5.5x10
2
 2.7x10
5
 0 
lung 0 0 0 0 0 0 0 0 1.2x10
3
 0 
brain 0 0 0 0 0 0 0 0 0 0 
BM 0 0 0 0 6.2x10
3
 0 0 0 0 1.2x10
3
 
peritoneum 0 0 0 0 0 1.0x10
2
 0 0 0 0 
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Supplement Table 3: Relative amounts (%) of human leukocyte subsets in the BM 
 lymphocytes
 
granulocytes
 
humanized  
mouse 
30 (19-41) 4.3 (-1-10) 
neonate 14 (3-25) 63 (43-83) 
adult 17 (10-24) 60 (40-84) 
Values represent the mean, with 95% confidence interval in parentheses. Values of neonate 
and adult BM (Greer et al. 2009) 
 
Supplement Table 4: Relative amounts (%) of human leukocyte subsets in the lung 
 B cells
#
 T cells
#
 
myeloid cells 
(macrophages)
 granulocytes
 
humanized  
mouse 
11 30 13 0.05 
adult <1 7-11 >80 <1-4 
Values of adult bronchoalveolar fluid (Harbeck 1998; Meyer 2007) 
 
Supplement Table 5: Relative amounts (%) of human leukocyte subsets in the peritoneum 
 B cells
#
 T cells
#
 
myeloid cells 
(macrophages)
 
humanized  
mouse 
2 6 4 
adult 2 8 45 
Values of adult peritoneal lavage (Harbeck 1998; Meyer 2007) 
 
Supplement Table 6: Relative amounts (%) of human leukocyte subsets in the LN 
 B cells
#
 T cells
#
 
humanized  
mouse 
32 
(±7) 
50 
(±12) 
adult 
41 
(±15) 
56 
(±13) 
Values represent the mean ± standard deviation in parentheses. Values of adult LNs 
(Battaglia et al. 2003). 
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ABBREVIATIONS 
 
°C degree Celsius 
µ micro 
µl microliter 
ACD Acid-Citrate-Dextrose 
ACK Ammonium-Chloride-Potassium 
ACP alpha C protein 
ADCC antibody dependent cellular cytotoxicity 
AIDS acquired immune deficiency syndrome 
AMP antimicrobial peptide 
ANOVA analysis of variance 
APC antigen presenting cell 
APC allophycocyanin 
APC-Cy7 allophycocyanin- cyanine 7 
ATCC American Type Culture Collection 
B2m β2 microglobulin 
BBB blood brain barrier 
BD Becton, Dickinson and Company 
BETA Betamethasone 
bg beige 
BibA GBS immunogenic bacterial adhesin 
BM bone marrow 
BMDC bone marrow derived cell 
BMDM bone marrow derived macrophage 
BSA bovine serum albumin 
C4BP C4b binding protein 
CAMP-factor Cristie-Atkins-Munch-Petersen-factor 
CCR chemokine receptor 
CD cluster of differentiation 
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CD40L CD40 ligand 
CDC Center of Disease Control 
CDC42 cell division control protein 42 
CFH complement factor H 
CFU colony forming unit 
COX cyclo-oxygenase 
CpG deoxycytidylate-phosphate-deoxyguanylate 
CPS capsular polysaccharide 
d day 
DC dendritic cells 
ddH2O double-distilled water 
dil. dilution 
DMSO dimethyl sulfoxide 
DPPC dipalmitoylphosphatidylcholine 
DTH delayed-type hypersensitivity 
E. coli Escherichia coli 
e.g. exempli gratia (for example) 
EBV Epstein Barr virus 
ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
EOD early onset disease 
et al. et aliae (and others) 
EtOH ethanol 
FACS fluorescence activated cell sorting 
FAK focal adhesion kinase 
FBS fetal bovine serum 
FbsA GBS fibrinogen binding protein 
Fc fragment crystallizable 
FcαRI Fc-alpha receptor I 
FcγRIIA/C Fc-gamma receptor II A/C 
Abbreviations    130 
Fig. Figure 
FITC fluorescein isothiocyanate 
FOXN1 forkhead-box N1 
g gram 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GBS group B streptococcus 
G-CSF granulocyte colony stimulating factor 
GE General Electric 
GM-CSF granulocyte/monocyte colony stimulating factor 
GVHD graft versus host disease 
Gy gray 
h hour 
H&E Hematoxilin & Eosin  
HBV hepatitis B virus 
HCV hepatitis C virus 
HIV human immunodeficiency virus 
HLA human leukocyte antigen 
HSC hematopoietic stem cell 
IDDM insulin-dependent diabetis mellitus 
IFN interferon 
Ig immunoglobulin 
IL interleukin 
IL-2R interleukin-2-receptor 
IL2rg interleukin-2-receptor γ-chain locus 
IL-2RG IL-2 receptor γ chain 
INDO Indomethacin 
INF infected 
ip intraperitoneally 
IP-10 interferon-inducible protein-10 
IVH intraventricular hemorrhage 
k kilo 
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l liter  
LAK lymphokine activated killer 
LCA leukocyte common antigen 
LD50 lethal dose, 50% 
Lmb GBS laminin binding adhesin 
LN lymph node 
LOD late onset disease 
LPS lipopolysaccharide 
LrrG leucine-rich repeat protein G 
LTA lipoteichoic acid 
m mili 
M molar 
m meter 
Mac-1 Macrophage 1 antigen 
MACS magnetic cell separation 
M-CSF macrophage colony-stimulating factor 
mg milligram 
MHC major histocompatibility complex 
min minute 
MIP macrophage inflammatory protein 
ml milliliter  
mLN mesenteric lymph node 
MNCs mononuclear cells 
mRNA messenger ribonucleic acid 
n number 
ND not determined 
NET neutrophil extracellular trap 
NIH National Institutes of Health 
NK natural killer 
NOD non-obese diabetic 
NOG NOD/LtSz-scid IL2rg-/- 
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NSAID non-steroidal anti-inflammatory drug 
NSG NOD/Shi-scid IL2rg-/- 
nu nude 
OD optical density 
OVA ovalbumin 
pb peripheral blood 
PBMC peripheral blood mononuclear cells 
PBS phosphate buffered saline 
PE phycoerythrin 
PEC peritoneal exudate cell 
Pe-Cy7 phycoerythrin-cyanine 7 
PEL peritoneal lavage 
PerCP peridinin-chlorophyll-protein complex 
PFA paraformaldehyde 
PG prostaglandin 
pg picogram 
PI3K phosphoinosiotide-3 kinase 
Pil GBS pilus protein  
poly I:C polyinosinic:polycytidylic acid 
Prf prolactin-releasing factor 
Prkdc protein kinase, DNA activated, catalytic polypeptide 
R&D Research & Diagnostics 
Rac1 Ras-related C3 botulinum toxin substrate 1 
RAG recombination activation gene 
Ras Rat sarcoma 
rcf relative centrifugal force 
RDS respiratory distress syndrome 
RhoA Ras homolog gene family, member A 
ROS reactive oxygen species 
rpm rounds per minute 
RPMI Roswell Park Memorial Institute 
Abbreviations    133 
RT room temperature 
SCF stem cell factor 
scid severe combined immunodeficiency 
ScpB Streptococcal C5a peptidase 
SIRPA Signal-regulatory protein alpha 
SIRS systemic inflammatory response syndrome 
SodA superoxide dismutase A 
SP surfactant protein 
SR-A scavenger receptor A 
SRC scid-repopulating cell 
Srr1 serine-rich repeat 1 
TCR T cell receptor 
TD T cell-dependent 
Th T helper 
TI T cell-independent  
TIP TNF- and iNOS-producing 
TLR Toll-like receptor 
TNF tumor necrosis factor 
Treg regulatory T cells 
USA United States of America 
v/v volume/volume 
W watt 
w/v weight/volume 
β-H/C β-haemolysin/cytolysin 
γc common γ-chain 
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